Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
24,300 | 2020-12-04 00:00:00 UTC | Noteworthy Friday Option Activity: SHW, AWK, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-shw-awk-abbv-2020-12-04 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Sherwin-Williams Co (Symbol: SHW), where a total of 2,607 contracts have traded so far, representing approximately 260,700 underlying shares. That amounts to about 51.7% of SHW's average daily trading volume over the... | Particularly high volume was seen for the $110 strike call option expiring January 15, 2021, with 12,202 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Below is a chart showing AWK's trailing twelve month trading history, with the $160 strike highlighted in orange: And... | Below is a chart showing AWK's trailing twelve month trading history, with the $160 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 44,305 contracts thus far today. That number of contracts represents approximately 4.4 million underlying shares, working out to a sizeable 50.7... | Particularly high volume was seen for the $110 strike call option expiring January 15, 2021, with 12,202 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Below is a chart showing AWK's trailing twelve month trading history, with the $160 strike highlighted in orange: And... | Below is a chart showing AWK's trailing twelve month trading history, with the $160 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 44,305 contracts thus far today. That number of contracts represents approximately 4.4 million underlying shares, working out to a sizeable 50.7... |
24,301 | 2020-12-04 00:00:00 UTC | What's Happening With Merck Stock? | ABBV | https://www.nasdaq.com/articles/whats-happening-with-merck-stock-2020-12-04 | null | null | [Updated 12/2/2020] Merck Update
Merck (NYSE: MRK) recently announced that it has sold its equity investment in Moderna. Merck has benefited from a whopping 7x surge in Moderna stock this year, given its Covid-19 vaccine development. Though, despite the recent rise, Moderna stock still looks attractive in our view.
Las... | Currently, AbbVie’s Humira is the largest selling drug across the globe with roughly $20 billion in annual sales, but it will face patent expiry in 2023. Last month, Merck announced the acquisition of VelosBio – a biotech company focused on targeting the ROR1 surface protein – to strengthen its oncology portfolio. This... | Currently, AbbVie’s Humira is the largest selling drug across the globe with roughly $20 billion in annual sales, but it will face patent expiry in 2023. Despite this impact, it has managed to expand its sales as well as earnings, primarily due to the continued market share gains for its blockbuster drug, Keytruda, a t... | Currently, AbbVie’s Humira is the largest selling drug across the globe with roughly $20 billion in annual sales, but it will face patent expiry in 2023. We know that Merck’s sales have been impacted by the Covid-19 pandemic, and the company estimates the impact to be $2.4 billion for the full year 2020. Merck now expe... | Currently, AbbVie’s Humira is the largest selling drug across the globe with roughly $20 billion in annual sales, but it will face patent expiry in 2023. At the current price of $81, it is trading at under 13x its 2021 expected EPS of $6.36, compared to levels of 18x seen over the recent years, implying the stock has m... |
24,302 | 2020-12-04 00:00:00 UTC | Reality Hits Home for Shares of Inovio Pharmaceuticals | ABBV | https://www.nasdaq.com/articles/reality-hits-home-for-shares-of-inovio-pharmaceuticals-2020-12-04 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Carried by enthusiasm for novel coronavirus vaccines, Inovio Pharmaceuticals (NASDAQ:INO) soared in the summer but INO stock has since settled about two-thirds lower.
INO) logo covered up by pills and a syringe" width="300" height="169">
Source: Ascannio / ... | Other pharma companies cited by Baglole were Regeneron Pharmaceuticals (NASDAQ:REGN), Abbvie (NYSE:ABBV) and Novavax (NASDAQ:NVAX). INO) logo covered up by pills and a syringe" width="300" height="169"> Source: Ascannio / Shutterstock.com The company grabbed some of the spotlight as its anti-coronavirus entry began a c... | Other pharma companies cited by Baglole were Regeneron Pharmaceuticals (NASDAQ:REGN), Abbvie (NYSE:ABBV) and Novavax (NASDAQ:NVAX). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Carried by enthusiasm for novel coronavirus vaccines, Inovio Pharmaceuticals (NASDAQ:INO) soared in the summer but INO stock ... | Other pharma companies cited by Baglole were Regeneron Pharmaceuticals (NASDAQ:REGN), Abbvie (NYSE:ABBV) and Novavax (NASDAQ:NVAX). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Carried by enthusiasm for novel coronavirus vaccines, Inovio Pharmaceuticals (NASDAQ:INO) soared in the summer but INO stock ... | Other pharma companies cited by Baglole were Regeneron Pharmaceuticals (NASDAQ:REGN), Abbvie (NYSE:ABBV) and Novavax (NASDAQ:NVAX). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Carried by enthusiasm for novel coronavirus vaccines, Inovio Pharmaceuticals (NASDAQ:INO) soared in the summer but INO stock ... |
24,303 | 2020-12-03 00:00:00 UTC | 3 Dividend Stocks for Big Total Returns in 2021 | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-for-big-total-returns-in-2021-2020-12-03 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The Federal Reserve slashed interest rates back in March in protecting the economy from the crippling economic effects of Covid-19. Dividend stocks became doubly important for investors, with savings yields taking a battering.
Thankfully, the pandemic-induc... | AbbVie (NYSE:ABBV) Johnson & Johnson (NYSE:JNJ) Medtronic (NYSE:MDT) Dividend Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com AbbVie is a multinational biopharmaceutical company that develops and sells pharmaceutical products in severa... | AbbVie (NYSE:ABBV) Johnson & Johnson (NYSE:JNJ) Medtronic (NYSE:MDT) Dividend Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com AbbVie is a multinational biopharmaceutical company that develops and sells pharmaceutical products in severa... | AbbVie (NYSE:ABBV) Johnson & Johnson (NYSE:JNJ) Medtronic (NYSE:MDT) Dividend Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com AbbVie is a multinational biopharmaceutical company that develops and sells pharmaceutical products in severa... | AbbVie (NYSE:ABBV) Johnson & Johnson (NYSE:JNJ) Medtronic (NYSE:MDT) Dividend Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com AbbVie is a multinational biopharmaceutical company that develops and sells pharmaceutical products in severa... |
24,304 | 2020-12-02 00:00:00 UTC | AbbVie, Frontier Medicines To Collaborate On Developing Novel Therapies And E3 Degraders | ABBV | https://www.nasdaq.com/articles/abbvie-frontier-medicines-to-collaborate-on-developing-novel-therapies-and-e3-degraders | null | null | (RTTNews) - AbbVie (ABBV) and Frontier Medicines Corp. said Wednesday they have entered into a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets.
Under the multi-year collaboration, AbbVie a... | (RTTNews) - AbbVie (ABBV) and Frontier Medicines Corp. said Wednesday they have entered into a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets. AbbVie said it retains the right to expand t... | In addition, AbbVie will reimburse Frontier's R&D costs through defined stages of pre-clinical development. (RTTNews) - AbbVie (ABBV) and Frontier Medicines Corp. said Wednesday they have entered into a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therape... | (RTTNews) - AbbVie (ABBV) and Frontier Medicines Corp. said Wednesday they have entered into a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets. Under the multi-year collaboration, AbbVie a... | Under the multi-year collaboration, AbbVie and Frontier will utilize Frontier's proprietary chemoproteomics platform to identify small molecules for programs directed to novel E3 ligases as well as certain oncology and immunology targets. (RTTNews) - AbbVie (ABBV) and Frontier Medicines Corp. said Wednesday they have e... |
24,305 | 2020-12-02 00:00:00 UTC | Despite A 65% Rally AbbVie Stock Looks Like It Can Gain More | ABBV | https://www.nasdaq.com/articles/despite-a-65-rally-abbvie-stock-looks-like-it-can-gain-more-2020-12-02 | null | null | AbbVie stock (NYSE: ABBV) is up 18% since the start of the year and it has gained around 62% from its March lows. Despite the recent rally, AbbVie could offer an upside in the near term, as the company’s revenues in the last three quarters have grown by 30%, primarily aided by the Allergan acquisition. AbbVie is also s... | Despite the recent rally, AbbVie could offer an upside in the near term, as the company’s revenues in the last three quarters have grown by 30%, primarily aided by the Allergan acquisition. The global spread of Coronavirus has meant there just aren’t many people visiting doctors for non-emergency cases, and several typ... | Better than estimated earnings in Q2 and Q3 has helped ABBV stock rally over the recent months. Another important drug for AbbVie is Imbruvica, which garnered $4.7 billion in sales in 2019, and its peak is estimated to be north of $7 billion. AbbVie stock (NYSE: ABBV) is up 18% since the start of the year and it has ga... | While Humira sales are expected to decline over the coming years (with the U.S. FDA approving its biosimilars), we believe AbbVie’s current portfolio as well as its robust pipeline will likely be able to more than offset it and bolster the company’s overall earnings growth. At levels of $105, ABBV stock is trading at j... | ABBV stock has rallied from $67 to $105 off the recent bottom compared to the S&P which moved 61% over the same time period. AbbVie stock (NYSE: ABBV) is up 18% since the start of the year and it has gained around 62% from its March lows. Despite the recent rally, AbbVie could offer an upside in the near term, as the c... |
24,306 | 2020-12-01 00:00:00 UTC | Notable ETF Outflow Detected - ACWI, V, ABBV, XOM | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-acwi-v-abbv-xom-2020-12-01 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI ACWI ETF (Symbol: ACWI) where we have detected an approximate $227.1 million dollar outflow -- that's a 1.6% decrease week over week (from 164,000,000 to 161,400,000). Among the... | Among the largest underlying components of ACWI, in trading today Visa Inc (Symbol: V) is up about 0.8%, AbbVie Inc (Symbol: ABBV) is up about 1.5%, and Exxon Mobil Corp (Symbol: XOM) is higher by about 3.9%. For a complete list of holdings, visit the ACWI Holdings page » The chart below shows the one year price perfor... | Among the largest underlying components of ACWI, in trading today Visa Inc (Symbol: V) is up about 0.8%, AbbVie Inc (Symbol: ABBV) is up about 1.5%, and Exxon Mobil Corp (Symbol: XOM) is higher by about 3.9%. For a complete list of holdings, visit the ACWI Holdings page » The chart below shows the one year price perfor... | Among the largest underlying components of ACWI, in trading today Visa Inc (Symbol: V) is up about 0.8%, AbbVie Inc (Symbol: ABBV) is up about 1.5%, and Exxon Mobil Corp (Symbol: XOM) is higher by about 3.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, o... | Among the largest underlying components of ACWI, in trading today Visa Inc (Symbol: V) is up about 0.8%, AbbVie Inc (Symbol: ABBV) is up about 1.5%, and Exxon Mobil Corp (Symbol: XOM) is higher by about 3.9%. For a complete list of holdings, visit the ACWI Holdings page » The chart below shows the one year price perfor... |
24,307 | 2020-12-01 00:00:00 UTC | 3 Pharma Stocks With Dividends Above 4% to Buy Now | ABBV | https://www.nasdaq.com/articles/3-pharma-stocks-with-dividends-above-4-to-buy-now-2020-12-01 | null | null | Investors looking for dividend-paying stocks that offer juicy yields right now can find what they're looking for in the biopharmaceutical industry.
All three of these big pharmaceutical companies have well-funded dividend programs that offer juicy yields above 4% right now.
COMPANY (SYMBOL) DIVIDEND YIELD TRAILING FREE... | AbbVie (NYSE: ABBV) 4.5% $15.3 billion Gilead Sciences (NASDAQ: GILD) 4.4% $8.2 billion Pfizer (NYSE: PFE) 4.2% $12.6 billion Data source: Yahoo! AbbVie Since spinning off from Abbott in 2013, AbbVie has raised its dividend payout a whopping 225% with help from its top-selling rheumatoid arthritis treatment, Humira. Th... | AbbVie (NYSE: ABBV) 4.5% $15.3 billion Gilead Sciences (NASDAQ: GILD) 4.4% $8.2 billion Pfizer (NYSE: PFE) 4.2% $12.6 billion Data source: Yahoo! AbbVie Since spinning off from Abbott in 2013, AbbVie has raised its dividend payout a whopping 225% with help from its top-selling rheumatoid arthritis treatment, Humira. Th... | AbbVie (NYSE: ABBV) 4.5% $15.3 billion Gilead Sciences (NASDAQ: GILD) 4.4% $8.2 billion Pfizer (NYSE: PFE) 4.2% $12.6 billion Data source: Yahoo! Gilead Sciences While Pfizer and AbbVie have enormous roots that go back generations, Gilead Sciences didn't begin producing profits for its shareholders until 2001. AbbVie S... | Thanks to contributions from AbbVie's enormous acquisition of Allergan earlier this year, the company relied on Humira for just 46% of total sales in the third quarter. Gilead Sciences While Pfizer and AbbVie have enormous roots that go back generations, Gilead Sciences didn't begin producing profits for its shareholde... |
24,308 | 2020-11-30 00:00:00 UTC | AbbVie (ABBV) Shares Cross 5% Yield Mark | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-shares-cross-5-yield-mark-2020-11-30 | null | null | Looking at the universe of stocks we cover at Dividend Channel, in trading on Monday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $5.2), with the stock changing hands as low as $103.65 on the day. Dividends are particularly important for investors t... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Monday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $5.2), with the stock changing hands as low as $103.65 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giv... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Monday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $5.2), with the stock changing hands as low as $103.65 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giv... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Monday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $5.2), with the stock changing hands as low as $103.65 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giv... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Monday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $5.2), with the stock changing hands as low as $103.65 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giv... |
24,309 | 2020-11-28 00:00:00 UTC | Is AbbVie a Great Dividend Stock? | ABBV | https://www.nasdaq.com/articles/is-abbvie-a-great-dividend-stock-2020-11-28 | null | null | Dividend investors sometimes fixate on a stock's yield to judge its greatness as an income investment. But that number is only part of the story, and arguably not the most important part.
A high dividend payout may simply mean that the company is prioritizing returning its cash flow to investors over reinvesting that c... | Meanwhile, AbbVie's portfolio, helped by some potential cancer drugs that are still in early days, is generating piles of cash that support the generous dividend while allowing the company to invest in growth. AbbVie ticks the boxes when it comes to dividend greatness, a conclusion apparently shared by Warren Buffett, ... | Dividend growth AbbVie split from Abbott Laboratories about eight years ago, but by virtue of the dividend history of its parent company, it earns the designation of Dividend Aristocrat. Does pharmaceutical giant AbbVie (NYSE: ABBV) measure up as a great dividend stock? AbbVie is doing both, but investors have been con... | Dividend growth AbbVie split from Abbott Laboratories about eight years ago, but by virtue of the dividend history of its parent company, it earns the designation of Dividend Aristocrat. Does pharmaceutical giant AbbVie (NYSE: ABBV) measure up as a great dividend stock? AbbVie is doing both, but investors have been con... | Does pharmaceutical giant AbbVie (NYSE: ABBV) measure up as a great dividend stock? AbbVie is doing both, but investors have been concerned about a headwind from generic competition to Humira, the world's top-selling drug, which will likely appear in the U.S. in 2023. Humira contributed about 40% of AbbVie's sales in t... |
24,310 | 2020-11-25 00:00:00 UTC | How is Abbvie Inc (NYSE: ABBV) Preparing For Life After Humira? | ABBV | https://www.nasdaq.com/articles/how-is-abbvie-inc-nyse%3A-abbv-preparing-for-life-after-humira-2020-11-25 | null | null | By Kshitija Bhandaru
Pharmaceutical company AbbVie Inc’s ( NYSE: ABBV ) stock was up last week after Warren Buffett’s company Berkshire Hathaway ( NYSE: BRK.A ) disclosed a $1.8 billion position in Abbvie in a regulatory filing. Abbvie stock rose 1% a day after the announcement and is up almost 6% over the past week.
... | However, while the deal did add size and scale, not to mention diversification to the company, it also brought additional baggage in the form of excessive debt- Abbvie assumed $23b of Allergan’s debt at the time of transaction. By Kshitija Bhandaru Pharmaceutical company AbbVie Inc’s ( NYSE: ABBV ) stock was up last we... | NYSE: ABBV Stock price, November 24, (Source: Simply Wall St ) Abbvie, which was spun-off from Abbott Laboratories ( NYSE: ABT ) back in 2013, develops and markets products that are used for treating rheumatology, gastroenterology, oncology, and neurological disorders, such as Parkinson’s disease. NYSE: ABBV Future Gro... | By Kshitija Bhandaru Pharmaceutical company AbbVie Inc’s ( NYSE: ABBV ) stock was up last week after Warren Buffett’s company Berkshire Hathaway ( NYSE: BRK.A ) disclosed a $1.8 billion position in Abbvie in a regulatory filing. ABBV’s efforts to address loss of Humira revenues One of the most significant steps taken ... | The drug accounted for almost 60% of ABBV’s revenues in FY 2019. While the price hikes have helped ABBV’s revenues so far, losing pricing power to competition, along with patent expiration can make the impact on the company’s revenues two-fold. NYSE: ABBV Future Growth, November 24, (Source: Simply Wall St ) In additio... |
24,311 | 2020-11-22 00:00:00 UTC | These 3 Dividend Stocks Are Practically Money Machines | ABBV | https://www.nasdaq.com/articles/these-3-dividend-stocks-are-practically-money-machines-2020-11-22 | null | null | Many investors buy dividend stocks for one reason: They want a reliable income stream.
Some stocks generate larger income streams, while others provide more reliability. If you're looking for both, check out these three dividend stocks.
1. AbbVie
You just might drool over AbbVie's (NYSE: ABBV) dividend yield of close t... | Could the looming entrance of biosimilar rivals to AbbVie's top-selling drug Humira in the U.S. market threaten the company's dividend? AbbVie You just might drool over AbbVie's (NYSE: ABBV) dividend yield of close to 5.2%. AbbVie is a Dividend Aristocrat -- a term for S&P 500 members that have increased their dividend... | See the 10 stocks *Stock Advisor returns as of October 20, 2020 Keith Speights owns shares of AbbVie, Brookfield Renewable Inc., Brookfield Renewable Partners L.P., and Innovative Industrial Properties. AbbVie You just might drool over AbbVie's (NYSE: ABBV) dividend yield of close to 5.2%. AbbVie is a Dividend Aristocr... | See the 10 stocks *Stock Advisor returns as of October 20, 2020 Keith Speights owns shares of AbbVie, Brookfield Renewable Inc., Brookfield Renewable Partners L.P., and Innovative Industrial Properties. AbbVie You just might drool over AbbVie's (NYSE: ABBV) dividend yield of close to 5.2%. AbbVie is a Dividend Aristocr... | See the 10 stocks *Stock Advisor returns as of October 20, 2020 Keith Speights owns shares of AbbVie, Brookfield Renewable Inc., Brookfield Renewable Partners L.P., and Innovative Industrial Properties. AbbVie You just might drool over AbbVie's (NYSE: ABBV) dividend yield of close to 5.2%. AbbVie is a Dividend Aristocr... |
24,312 | 2020-11-21 00:00:00 UTC | Like Dividends? I Bet You'll Love These 3 Stocks | ABBV | https://www.nasdaq.com/articles/like-dividends-i-bet-youll-love-these-3-stocks-2020-11-21 | null | null | Investment fads come and go, and growth stories eventually end. Income-producing stocks always fit into a portfolio, however, even if those dividends are being collected to purchase other sorts of positions. And, given the uncertainty that lies in our immediate future, a little more certainty and a little less risk cer... | The company completed its acquisition of Allergan in May of this year, adding drug franchises (Botox in particular) that produce about $20 billion in annual sales to AbbVie's portfolio. At the same time, AbbVie's home-grown drug pipeline currently includes about a couple dozen phase 3 trials that could wrap up and be s... | AbbVie Dividend yield: 5.3% Drug company AbbVie is another Dividend Aristocrat. To this end, investors looking to fill in some gaps with any idle cash right now may want to look at Colgate-Palmolive (NYSE: CL), AbbVie (NYSE: ABBV), and McDonald's (NYSE: MCD). AbbVie finds itself in this very position, in fact. | AbbVie Dividend yield: 5.3% Drug company AbbVie is another Dividend Aristocrat. To this end, investors looking to fill in some gaps with any idle cash right now may want to look at Colgate-Palmolive (NYSE: CL), AbbVie (NYSE: ABBV), and McDonald's (NYSE: MCD). AbbVie finds itself in this very position, in fact. | At the same time, AbbVie's home-grown drug pipeline currently includes about a couple dozen phase 3 trials that could wrap up and be submitted to the FDA for approval before Humira's patent protection expires. To this end, investors looking to fill in some gaps with any idle cash right now may want to look at Colgate-P... |
24,313 | 2020-11-21 00:00:00 UTC | 3 High-Yield Dividend Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-to-buy-now-2020-11-21 | null | null | Sometimes, a high dividend yield is a sign that investors are worried about challenges to a business that puts those payouts in jeopardy. Often, the market is right, but sometimes, it's slow to respond to improving conditions.
The three companies below all have yields of 4.5% or higher, a nice income stream at a time w... | AbbVie could very well experience some quarters of unimpressive growth due to Humira losses, but the company also has a strong pipeline of cancer drugs and some neurology candidates that could be winners. AbbVie Investors have been wary of pharmaceutical-giant AbbVie (NYSE: ABBV) because of competitive threats to Humir... | AbbVie Investors have been wary of pharmaceutical-giant AbbVie (NYSE: ABBV) because of competitive threats to Humira, the world's top-selling drug, which faces generic competition in the U.S. in 2023. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Jim Crumly owns shares of Abbott Laboratories, AbbVie, ... | AbbVie Investors have been wary of pharmaceutical-giant AbbVie (NYSE: ABBV) because of competitive threats to Humira, the world's top-selling drug, which faces generic competition in the U.S. in 2023. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Jim Crumly owns shares of Abbott Laboratories, AbbVie, ... | AbbVie Investors have been wary of pharmaceutical-giant AbbVie (NYSE: ABBV) because of competitive threats to Humira, the world's top-selling drug, which faces generic competition in the U.S. in 2023. It's no wonder that the most famous value investor of all, Warren Buffett, opened a position in AbbVie just last quarte... |
24,314 | 2020-11-20 00:00:00 UTC | ACWI, PEP, ABBV, QCOM: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/acwi-pep-abbv-qcom%3A-etf-inflow-alert-2020-11-20 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI ACWI ETF (Symbol: ACWI) where we have detected an approximate $207.7 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 161,600,000 to 164... | Among the largest underlying components of ACWI, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.1%, and Qualcomm Inc (Symbol: QCOM) is higher by about 0.6%. For a complete list of holdings, visit the ACWI Holdings page » The chart below shows the one year price perf... | Among the largest underlying components of ACWI, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.1%, and Qualcomm Inc (Symbol: QCOM) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... | Among the largest underlying components of ACWI, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.1%, and Qualcomm Inc (Symbol: QCOM) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... | Among the largest underlying components of ACWI, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.1%, and Qualcomm Inc (Symbol: QCOM) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... |
24,315 | 2020-11-20 00:00:00 UTC | Warren Buffett Just Bought These Stocks | ABBV | https://www.nasdaq.com/articles/warren-buffett-just-bought-these-stocks-2020-11-20 | null | null | A knack for buying great stocks has made Warren Buffett one of the world's richest people, according to Forbes. That kind of success suggests it's smart to buy the same stocks he does. Fortunately, Warren Buffett's company, Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B), discloses its latest transactions in a 13-F fili... | Its latest filing reveals that Berkshire Hathaway's established new positions in the big-cap pharmaceutical stocks AbbVie, Bristol Myers Squibb, Merck, and Pfizer. Company Shares Bought Current Value Bristol Myers Squibb (NYSE: BMY) 29.9 million $1.81 billion AbbVie (NYSE: ABBV) 21.3 million $1.86 billion Merck (NYSE: ... | Company Shares Bought Current Value Bristol Myers Squibb (NYSE: BMY) 29.9 million $1.81 billion AbbVie (NYSE: ABBV) 21.3 million $1.86 billion Merck (NYSE: MRK) 22.4 million $1.86 billion Pfizer (NYSE: PFE) 3.7 million $136 million Warren Buffett's decision to buy Bristol Myers Squibb, AbbVie, Merck, and Pfizer may als... | Company Shares Bought Current Value Bristol Myers Squibb (NYSE: BMY) 29.9 million $1.81 billion AbbVie (NYSE: ABBV) 21.3 million $1.86 billion Merck (NYSE: MRK) 22.4 million $1.86 billion Pfizer (NYSE: PFE) 3.7 million $136 million Warren Buffett's decision to buy Bristol Myers Squibb, AbbVie, Merck, and Pfizer may als... | Its latest filing reveals that Berkshire Hathaway's established new positions in the big-cap pharmaceutical stocks AbbVie, Bristol Myers Squibb, Merck, and Pfizer. Company Shares Bought Current Value Bristol Myers Squibb (NYSE: BMY) 29.9 million $1.81 billion AbbVie (NYSE: ABBV) 21.3 million $1.86 billion Merck (NYSE: ... |
24,316 | 2020-11-18 00:00:00 UTC | ANALYSIS-Berkshire's bet a bright spot in gloomy year for Big Pharma stocks | ABBV | https://www.nasdaq.com/articles/analysis-berkshires-bet-a-bright-spot-in-gloomy-year-for-big-pharma-stocks-2020-11-18 | null | null | By Lewis Krauskopf
NEW YORK, Nov 18 (Reuters) - Berkshire Hathaway Inc's BRKa.N new bet on the U.S. pharmaceutical industry signals hope for shares of large drug companies, which have lagged a broad market rally amid concern about efforts to rein in prescription drug prices.
Drug stocks largely outperformed on Tuesday,... | Drug stocks largely outperformed on Tuesday, a day after Warren Buffett's conglomerate, long underweight in the healthcare sector, revealed $5.7 billion of new investments in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N, whose vaccine has demonstrated effectiveness in late-sta... | Drug stocks largely outperformed on Tuesday, a day after Warren Buffett's conglomerate, long underweight in the healthcare sector, revealed $5.7 billion of new investments in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N, whose vaccine has demonstrated effectiveness in late-sta... | Drug stocks largely outperformed on Tuesday, a day after Warren Buffett's conglomerate, long underweight in the healthcare sector, revealed $5.7 billion of new investments in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N, whose vaccine has demonstrated effectiveness in late-sta... | Drug stocks largely outperformed on Tuesday, a day after Warren Buffett's conglomerate, long underweight in the healthcare sector, revealed $5.7 billion of new investments in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N, whose vaccine has demonstrated effectiveness in late-sta... |
24,317 | 2020-11-18 00:00:00 UTC | Is Moderna Still a Compelling Growth Play? | ABBV | https://www.nasdaq.com/articles/is-moderna-still-a-compelling-growth-play-2020-11-18 | null | null | Moderna (NASDAQ: MRNA) has had a banner year in 2020. Thanks to the biotech's COVID-19 vaccine candidate mRNA-1273, the company's shares have gapped up by an eye-catching 400% this year.
The biotech's red-hot growth streak, though, may be nearing an end. BMO Capital analyst George Farmer, for instance, said earlier thi... | If one or more of these early vaccines do indeed confer long-lasting immunity, the COVID-19 vaccine space should quickly evaporate in a manner akin to the hepatitis C drug market following the introduction of effective cures from AbbVie and Gilead Sciences. In effect, Astra's, J&J's, and Novavax's vaccine candidates mi... | If one or more of these early vaccines do indeed confer long-lasting immunity, the COVID-19 vaccine space should quickly evaporate in a manner akin to the hepatitis C drug market following the introduction of effective cures from AbbVie and Gilead Sciences. Thanks to the biotech's COVID-19 vaccine candidate mRNA-1273, ... | If one or more of these early vaccines do indeed confer long-lasting immunity, the COVID-19 vaccine space should quickly evaporate in a manner akin to the hepatitis C drug market following the introduction of effective cures from AbbVie and Gilead Sciences. Moderna's COVID-19 opportunity For a multitude of reasons, Mod... | If one or more of these early vaccines do indeed confer long-lasting immunity, the COVID-19 vaccine space should quickly evaporate in a manner akin to the hepatitis C drug market following the introduction of effective cures from AbbVie and Gilead Sciences. Moderna (NASDAQ: MRNA) has had a banner year in 2020. That doe... |
24,318 | 2020-11-18 00:00:00 UTC | Here's Exactly Why Warren Buffett Loaded Up on Big Pharma Stocks | ABBV | https://www.nasdaq.com/articles/heres-exactly-why-warren-buffett-loaded-up-on-big-pharma-stocks-2020-11-18 | null | null | We now know which stocks Warren Buffett's Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) added to its portfolio in the third quarter. The giant conglomerate's regulatory filing to the U.S. Securities and Exchange Commission on Monday revealed that Buffett appears to be quite bullish on big pharma.
Berkshire's new posit... | Berkshire's new positions in Q3 included four of the biggest drugmakers on the market: AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Merck (NYSE: MRK), and Pfizer (NYSE: PFE). AbbVie, for example, trades at only a little over eight times expected earnings. Bristol Myers Squibb's forward earnings multiple is ju... | Berkshire's new positions in Q3 included four of the biggest drugmakers on the market: AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Merck (NYSE: MRK), and Pfizer (NYSE: PFE). AbbVie, for example, trades at only a little over eight times expected earnings. Bristol Myers Squibb's forward earnings multiple is ju... | Berkshire's new positions in Q3 included four of the biggest drugmakers on the market: AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Merck (NYSE: MRK), and Pfizer (NYSE: PFE). See the 10 stocks *Stock Advisor returns as of October 20, 2020 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), Br... | That's exactly what Buffett and Berkshire will get with AbbVie, BMS, Merck, and Pfizer. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), Bristol Myers Squibb, and Pfizer. Berkshire's new positions in Q3 included four of the biggest drug... |
24,319 | 2020-11-17 00:00:00 UTC | Despite Buffett Bullishness, Stock Markets Are Falling | ABBV | https://www.nasdaq.com/articles/despite-buffett-bullishness-stock-markets-are-falling-2020-11-17 | null | null | There's been considerable volatility in the market, and in conditions like this, investors often look for guidance from experts. There are few investors more people look up to than Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett.
Every three months, investors get to find out what stocks Berkshire Hath... | Buffett added shares of Merck (NYSE: MRK), Bristol-Myers Squibb (NYSE: BMY), Pfizer (NYSE: PFE), and AbbVie (NYSE: ABBV) to the Berkshire portfolio. It's a great window into the mind of Buffett and his peers at Berkshire, and it can be a plentiful source for stock ideas even when the overall market isn't performing the... | Buffett added shares of Merck (NYSE: MRK), Bristol-Myers Squibb (NYSE: BMY), Pfizer (NYSE: PFE), and AbbVie (NYSE: ABBV) to the Berkshire portfolio. There are few investors more people look up to than Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett. The Motley Fool owns shares of and recommends Berksh... | Buffett added shares of Merck (NYSE: MRK), Bristol-Myers Squibb (NYSE: BMY), Pfizer (NYSE: PFE), and AbbVie (NYSE: ABBV) to the Berkshire portfolio. 10 stocks we like better than Berkshire Hathaway (B shares) When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. See the 10 stocks *Stock ... | Buffett added shares of Merck (NYSE: MRK), Bristol-Myers Squibb (NYSE: BMY), Pfizer (NYSE: PFE), and AbbVie (NYSE: ABBV) to the Berkshire portfolio. Berkshire Hathaway CEO Warren Buffett. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Berkshire Hathaway (B ... |
24,320 | 2020-11-17 00:00:00 UTC | US STOCKS-S&P 500, Dow drop from record levels as coronavirus cases spike | ABBV | https://www.nasdaq.com/articles/us-stocks-sp-500-dow-drop-from-record-levels-as-coronavirus-cases-spike-2020-11-17 | null | null | By Shivani Kumaresan and Medha Singh
Nov 17 (Reuters) - Wall Street's main indexes fell on Tuesday with the S&P 500 and the Dow retreating from record closing highs hit a day earlier, following disappointing retail sales data and a spike in coronavirus cases across the country.
The Nasdaq's losses were limited by a 12%... | Warren Buffett's Berkshire Hathaway Inc BRKa.N disclosed new stakes worth $5.7 billion in drugmakers Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N, lifting their shares between 1.4% and 2.4%. By Shivani Kumaresan and Medha Singh Nov 17 (Reuters) - Wall Street's main indexes fel... | Warren Buffett's Berkshire Hathaway Inc BRKa.N disclosed new stakes worth $5.7 billion in drugmakers Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N, lifting their shares between 1.4% and 2.4%. By Shivani Kumaresan and Medha Singh Nov 17 (Reuters) - Wall Street's main indexes fel... | Warren Buffett's Berkshire Hathaway Inc BRKa.N disclosed new stakes worth $5.7 billion in drugmakers Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N, lifting their shares between 1.4% and 2.4%. By Shivani Kumaresan and Medha Singh Nov 17 (Reuters) - Wall Street's main indexes fel... | Warren Buffett's Berkshire Hathaway Inc BRKa.N disclosed new stakes worth $5.7 billion in drugmakers Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N, lifting their shares between 1.4% and 2.4%. By Shivani Kumaresan and Medha Singh Nov 17 (Reuters) - Wall Street's main indexes fel... |
24,321 | 2020-11-17 00:00:00 UTC | US STOCKS-S&P, Dow futures retreat as coronavirus cases spike | ABBV | https://www.nasdaq.com/articles/us-stocks-sp-dow-futures-retreat-as-coronavirus-cases-spike-2020-11-17 | null | null | By Shivani Kumaresan and Medha Singh
Nov 17 (Reuters) - The S&P 500 and the Dow were set to open lower on Tuesday, retreating from record closing highs a day earlier as more U.S. states took measures to contain the COVID-19 pandemic.
The Nasdaq 100 futures NQcv1 rose 0.3% as Tesla Inc's TSLA.O shares soared 12.6% prema... | Warren Buffett's Berkshire Hathaway Inc BRKa.N disclosed new stakes worth $5.7 billion in drugmakers Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N, lifting their shares between 1.1% and 2.7%. By Shivani Kumaresan and Medha Singh Nov 17 (Reuters) - The S&P 500 and the Dow were s... | Warren Buffett's Berkshire Hathaway Inc BRKa.N disclosed new stakes worth $5.7 billion in drugmakers Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N, lifting their shares between 1.1% and 2.7%. The Nasdaq 100 futures NQcv1 rose 0.3% as Tesla Inc's TSLA.O shares soared 12.6% prema... | Warren Buffett's Berkshire Hathaway Inc BRKa.N disclosed new stakes worth $5.7 billion in drugmakers Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N, lifting their shares between 1.1% and 2.7%. By Shivani Kumaresan and Medha Singh Nov 17 (Reuters) - The S&P 500 and the Dow were s... | Warren Buffett's Berkshire Hathaway Inc BRKa.N disclosed new stakes worth $5.7 billion in drugmakers Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N, lifting their shares between 1.1% and 2.7%. The Nasdaq 100 futures NQcv1 rose 0.3% as Tesla Inc's TSLA.O shares soared 12.6% prema... |
24,322 | 2020-11-17 00:00:00 UTC | Buffett’s Berkshire Hathaway Buys New Stakes in Vaccine Makers, Cuts Banks | ABBV | https://www.nasdaq.com/articles/buffetts-berkshire-hathaway-buys-new-stakes-in-vaccine-makers-cuts-banks-2020-11-17 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Warren Buffett’s Berkshire Hathaway (NYSE:BRK.A, NYSE:BRK.B) has disclosed new stakes in Merck (NYSE:MRK), AbbVie (NYSE:ABBV), Pfizer (NYSE:PFE) and Bristol-Myers Squibb (NYSE:BMY), Bloomberg reported, citing a regulatory filing.
Source: Krista Kennell / Sh... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Warren Buffett’s Berkshire Hathaway (NYSE:BRK.A, NYSE:BRK.B) has disclosed new stakes in Merck (NYSE:MRK), AbbVie (NYSE:ABBV), Pfizer (NYSE:PFE) and Bristol-Myers Squibb (NYSE:BMY), Bloomberg reported, citing a regulatory filing. Buffett’s company had stake... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Warren Buffett’s Berkshire Hathaway (NYSE:BRK.A, NYSE:BRK.B) has disclosed new stakes in Merck (NYSE:MRK), AbbVie (NYSE:ABBV), Pfizer (NYSE:PFE) and Bristol-Myers Squibb (NYSE:BMY), Bloomberg reported, citing a regulatory filing. Buffett’s company had stake... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Warren Buffett’s Berkshire Hathaway (NYSE:BRK.A, NYSE:BRK.B) has disclosed new stakes in Merck (NYSE:MRK), AbbVie (NYSE:ABBV), Pfizer (NYSE:PFE) and Bristol-Myers Squibb (NYSE:BMY), Bloomberg reported, citing a regulatory filing. Buffett’s company had stake... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Warren Buffett’s Berkshire Hathaway (NYSE:BRK.A, NYSE:BRK.B) has disclosed new stakes in Merck (NYSE:MRK), AbbVie (NYSE:ABBV), Pfizer (NYSE:PFE) and Bristol-Myers Squibb (NYSE:BMY), Bloomberg reported, citing a regulatory filing. Buffett’s company had stake... |
24,323 | 2020-11-16 00:00:00 UTC | Warren Buffett Bought 4 Pharma Giants in Q3 | ABBV | https://www.nasdaq.com/articles/warren-buffett-bought-4-pharma-giants-in-q3-2020-11-16 | null | null | Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) filed its Form 13F with the Securities and Exchange Commission on Monday, which gave investors a look at what the Oracle of Omaha and his team of investors bought in the third quarter.
Among the list were four pharmaceutical companies: AbbVie (NYSE: ABBV), Merck (NYSE: MRK... | Among the list were four pharmaceutical companies: AbbVie (NYSE: ABBV), Merck (NYSE: MRK), Bristol Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE). AbbVie is looking to diversify away from its reliance on its megablockbuster Humira, which treats a variety of inflammatory disorders. Merck is hanging its hat on Keytruda... | Among the list were four pharmaceutical companies: AbbVie (NYSE: ABBV), Merck (NYSE: MRK), Bristol Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE). AbbVie is looking to diversify away from its reliance on its megablockbuster Humira, which treats a variety of inflammatory disorders. Berkshire Hathaway (NYSE: BRK.A) (NY... | Among the list were four pharmaceutical companies: AbbVie (NYSE: ABBV), Merck (NYSE: MRK), Bristol Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE). AbbVie is looking to diversify away from its reliance on its megablockbuster Humira, which treats a variety of inflammatory disorders. 10 stocks we like better than Pfizer... | Among the list were four pharmaceutical companies: AbbVie (NYSE: ABBV), Merck (NYSE: MRK), Bristol Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE). AbbVie is looking to diversify away from its reliance on its megablockbuster Humira, which treats a variety of inflammatory disorders. After all, the newsletter they have ... |
24,324 | 2020-11-16 00:00:00 UTC | Here Are the Stocks Warren Buffett Has Been Buying and Selling | ABBV | https://www.nasdaq.com/articles/here-are-the-stocks-warren-buffett-has-been-buying-and-selling-2020-11-16 | null | null | When Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) released its third-quarter earnings report, we learned that Warren Buffett and his team had quite an active quarter in the stock market. The cost basis of Berkshire's massive stock portfolio increased by about $9.6 billion, and it appeared that there had been some sell... | Buffett (or one of his stock pickers) initiated stakes worth nearly $6 billion altogether, including three large and nearly equal-sized positions in AbbVie, Merck, and Bristol Myers. Bank of America (NYSE: BAC) 85,092,006 $2.35 billion No Snowflake (NYSE: SNOW) 6,125,376 $1.44 billion Yes General Motors (NYSE: GM) 5,31... | Bank of America (NYSE: BAC) 85,092,006 $2.35 billion No Snowflake (NYSE: SNOW) 6,125,376 $1.44 billion Yes General Motors (NYSE: GM) 5,319,000 $224 million No AbbVie (NYSE: ABBV) 21,264,316 $1.86 billion Yes Merck (NYSE: MRK) 22,403,102 $1.86 billion Yes Bristol Myers (NYSE: BMY) 29,971,194 $1.81 billion Yes Kroger (NY... | Bank of America (NYSE: BAC) 85,092,006 $2.35 billion No Snowflake (NYSE: SNOW) 6,125,376 $1.44 billion Yes General Motors (NYSE: GM) 5,319,000 $224 million No AbbVie (NYSE: ABBV) 21,264,316 $1.86 billion Yes Merck (NYSE: MRK) 22,403,102 $1.86 billion Yes Bristol Myers (NYSE: BMY) 29,971,194 $1.81 billion Yes Kroger (NY... | Bank of America (NYSE: BAC) 85,092,006 $2.35 billion No Snowflake (NYSE: SNOW) 6,125,376 $1.44 billion Yes General Motors (NYSE: GM) 5,319,000 $224 million No AbbVie (NYSE: ABBV) 21,264,316 $1.86 billion Yes Merck (NYSE: MRK) 22,403,102 $1.86 billion Yes Bristol Myers (NYSE: BMY) 29,971,194 $1.81 billion Yes Kroger (NY... |
24,325 | 2020-11-16 00:00:00 UTC | Buffett's Berkshire invests in several big drugmakers | ABBV | https://www.nasdaq.com/articles/buffetts-berkshire-invests-in-several-big-drugmakers-2020-11-16 | null | null | Nov 16 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it has begun investing in four large drugmakers.
In a regulatory filing detailing its U.S.-listed investments as of Sept. 30, Berkshire disclosed new stakes in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer I... | In a regulatory filing detailing its U.S.-listed investments as of Sept. 30, Berkshire disclosed new stakes in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N. Nov 16 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it has begun investing in four large dr... | In a regulatory filing detailing its U.S.-listed investments as of Sept. 30, Berkshire disclosed new stakes in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N. Nov 16 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it has begun investing in four large dr... | In a regulatory filing detailing its U.S.-listed investments as of Sept. 30, Berkshire disclosed new stakes in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N. Investors monitor Omaha, Nebraska-based Berkshire's quarterly filings to see where Buffett and his portfolio managers To... | In a regulatory filing detailing its U.S.-listed investments as of Sept. 30, Berkshire disclosed new stakes in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N, Merck & Co MRK.N and Pfizer Inc PFE.N. Nov 16 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it has begun investing in four large dr... |
24,326 | 2020-11-16 00:00:00 UTC | 3 Recession Proof Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/3-recession-proof-stocks-to-buy-now-2020-11-16 | null | null | Rising COVID-19 infection rates, high unemployment, struggling small businesses, ongoing trade wars, and civil unrest all have some investors fearing the current recession will continue into 2021. A recession and stock market downturn are especially problematic for early retirees or people approaching retirement, becau... | AbbVie: A drug company with a stable portfolio and strong dividend Healthcare stocks are often considered recession-proof, though this designation requires some qualifiers. AbbVie (NYSE: ABBV) owns several massive-selling pharmaceutical drugs, including Humira, Botox, Venclexta, and Imbruvica. AbbVie is an interesting ... | AbbVie: A drug company with a stable portfolio and strong dividend Healthcare stocks are often considered recession-proof, though this designation requires some qualifiers. AbbVie (NYSE: ABBV) owns several massive-selling pharmaceutical drugs, including Humira, Botox, Venclexta, and Imbruvica. AbbVie is an interesting ... | AbbVie: A drug company with a stable portfolio and strong dividend Healthcare stocks are often considered recession-proof, though this designation requires some qualifiers. AbbVie (NYSE: ABBV) owns several massive-selling pharmaceutical drugs, including Humira, Botox, Venclexta, and Imbruvica. AbbVie is an interesting ... | AbbVie: A drug company with a stable portfolio and strong dividend Healthcare stocks are often considered recession-proof, though this designation requires some qualifiers. AbbVie (NYSE: ABBV) owns several massive-selling pharmaceutical drugs, including Humira, Botox, Venclexta, and Imbruvica. AbbVie is an interesting ... |
24,327 | 2020-11-15 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 11/15/2020 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-11-15-2020-2020-11-15 | null | null | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
ALIGN TECHNOLOGY, INC. (ALGN) is a lar... | Detailed Analysis of QUEST DIAGNOSTICS INC Full Guru Analysis for DGX> Full Factor Report for DGX> ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analy... | Detailed Analysis of QUEST DIAGNOSTICS INC Full Guru Analysis for DGX> Full Factor Report for DGX> ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analy... | Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV> Full Factor Report for ABBV> More details on Validea's John Neff strategy About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. Det... | Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV> Full Factor Report for ABBV> More details on Validea's John Neff strategy About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. Det... |
24,328 | 2020-11-13 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-2020-11-13 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Carlisle Companies Inc. (Symbol: CSL) $139.00 $156.50 12.59% Air Products & Chemicals Inc (Symbol: APD) $265.31 $296.50 11.76% AbbVie Inc (Symbol: ABBV) $97.60 $108.43 11.09% Sonoco Products Co. (Symbol: SON) $54.53 $59.12 8.43% Genuine Parts Co. (Symbol: GPC) $95.93 $101.67 5.98% The average 12-month analyst targets a... | Carlisle Companies Inc. (Symbol: CSL) $139.00 $156.50 12.59% Air Products & Chemicals Inc (Symbol: APD) $265.31 $296.50 11.76% AbbVie Inc (Symbol: ABBV) $97.60 $108.43 11.09% Sonoco Products Co. (Symbol: SON) $54.53 $59.12 8.43% Genuine Parts Co. (Symbol: GPC) $95.93 $101.67 5.98% The average 12-month analyst targets a... | Carlisle Companies Inc. (Symbol: CSL) $139.00 $156.50 12.59% Air Products & Chemicals Inc (Symbol: APD) $265.31 $296.50 11.76% AbbVie Inc (Symbol: ABBV) $97.60 $108.43 11.09% Sonoco Products Co. (Symbol: SON) $54.53 $59.12 8.43% Genuine Parts Co. (Symbol: GPC) $95.93 $101.67 5.98% The average 12-month analyst targets a... | Carlisle Companies Inc. (Symbol: CSL) $139.00 $156.50 12.59% Air Products & Chemicals Inc (Symbol: APD) $265.31 $296.50 11.76% AbbVie Inc (Symbol: ABBV) $97.60 $108.43 11.09% Sonoco Products Co. (Symbol: SON) $54.53 $59.12 8.43% Genuine Parts Co. (Symbol: GPC) $95.93 $101.67 5.98% The average 12-month analyst targets a... |
24,329 | 2020-11-12 00:00:00 UTC | Does Good News About Biogen's Alzheimer's Drug Mean Bad News for Rivals? | ABBV | https://www.nasdaq.com/articles/does-good-news-about-biogens-alzheimers-drug-mean-bad-news-for-rivals-2020-11-12 | null | null | Shares in Biogen (NASDAQ: BIIB) were up 44% on Wednesday, Nov. 4, to a high of $359.95 after a U.S. Food and Drug Administration (FDA) clinical review signaled that the biotech's phase 3 study on aducanumab showed the drug's effectiveness in slowing the progression of Alzheimer's disease.
This was in advance of the FDA... | Alector's shares also rose last week Alector, which is also headquartered in south San Francisco, has a trio of potential Alzheimer's therapies and its own deep-pocketed collaborator in AbbVie (NYSE: ABBV). See the 10 stocks *Stock Advisor returns as of October 20, 2020 Jim Halley owns shares of AbbVie. The companies e... | Alector's shares also rose last week Alector, which is also headquartered in south San Francisco, has a trio of potential Alzheimer's therapies and its own deep-pocketed collaborator in AbbVie (NYSE: ABBV). See the 10 stocks *Stock Advisor returns as of October 20, 2020 Jim Halley owns shares of AbbVie. Shares in Bioge... | Alector's shares also rose last week Alector, which is also headquartered in south San Francisco, has a trio of potential Alzheimer's therapies and its own deep-pocketed collaborator in AbbVie (NYSE: ABBV). See the 10 stocks *Stock Advisor returns as of October 20, 2020 Jim Halley owns shares of AbbVie. Shares in Bioge... | Alector's shares also rose last week Alector, which is also headquartered in south San Francisco, has a trio of potential Alzheimer's therapies and its own deep-pocketed collaborator in AbbVie (NYSE: ABBV). See the 10 stocks *Stock Advisor returns as of October 20, 2020 Jim Halley owns shares of AbbVie. Biogen says adu... |
24,330 | 2020-11-12 00:00:00 UTC | 4 Dividend Stocks With Yields Over 5% | ABBV | https://www.nasdaq.com/articles/4-dividend-stocks-with-yields-over-5-2020-11-12 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It’s dangerous to buy dividend stocks solely for their high yields. Even a cursory look at recent performance shows the risk.
Widely-held names like IBM (NYSE:IBM), AT&T (NYSE:T), and Altria (NYSE:MO) for years have seemed attractive due to dividend yields ... | 7 Solar Stocks to Buy for Biden’s Green Wave For these four dividend stocks that yield more than 5%, such a bull case exists: AbbVie (NYSE:ABBV) B&G Foods (NYSE:BGS) VICI Properties (NYSE:VICI) FirstEnergy (NYSE:FE) 4 Dividend Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Large-cap pharma has not been a g... | 7 Solar Stocks to Buy for Biden’s Green Wave For these four dividend stocks that yield more than 5%, such a bull case exists: AbbVie (NYSE:ABBV) B&G Foods (NYSE:BGS) VICI Properties (NYSE:VICI) FirstEnergy (NYSE:FE) 4 Dividend Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Large-cap pharma has not been a g... | 7 Solar Stocks to Buy for Biden’s Green Wave For these four dividend stocks that yield more than 5%, such a bull case exists: AbbVie (NYSE:ABBV) B&G Foods (NYSE:BGS) VICI Properties (NYSE:VICI) FirstEnergy (NYSE:FE) 4 Dividend Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Large-cap pharma has not been a g... | 7 Solar Stocks to Buy for Biden’s Green Wave For these four dividend stocks that yield more than 5%, such a bull case exists: AbbVie (NYSE:ABBV) B&G Foods (NYSE:BGS) VICI Properties (NYSE:VICI) FirstEnergy (NYSE:FE) 4 Dividend Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Large-cap pharma has not been a g... |
24,331 | 2020-11-10 00:00:00 UTC | AbbVie: Health Canada Okays Maviret For Patients With Genotype 3 Compensated Cirrhosis | ABBV | https://www.nasdaq.com/articles/abbvie%3A-health-canada-okays-maviret-for-patients-with-genotype-3-compensated-cirrhosis | null | null | (RTTNews) - AbbVie Inc. (ABBV) said Tuesday that Health Canada has approved a label change for Maviret (glecaprevir/pibrentasvir tablets) to include Treatment-Naïve Genotype 3 patients with compensated cirrhosis.
With this change, the recommended treatment duration for all individuals with chronic hepatitis C virus or ... | (RTTNews) - AbbVie Inc. (ABBV) said Tuesday that Health Canada has approved a label change for Maviret (glecaprevir/pibrentasvir tablets) to include Treatment-Naïve Genotype 3 patients with compensated cirrhosis. Through meaningful partnerships, we are working to find sustainable solutions that allow more patients to b... | Abbvie noted that Maviret's efficacy and safety were evaluated in nine phase II and III clinical trials, in over 2,300 patients with genotype 1, 2, 3, 4, 5 or 6 HCV infection and with compensated liver disease, with or without cirrhosis. (RTTNews) - AbbVie Inc. (ABBV) said Tuesday that Health Canada has approved a labe... | (RTTNews) - AbbVie Inc. (ABBV) said Tuesday that Health Canada has approved a label change for Maviret (glecaprevir/pibrentasvir tablets) to include Treatment-Naïve Genotype 3 patients with compensated cirrhosis. "AbbVie is committed to eliminating hepatitis C by 2030 and sees this objective as a national public health... | (RTTNews) - AbbVie Inc. (ABBV) said Tuesday that Health Canada has approved a label change for Maviret (glecaprevir/pibrentasvir tablets) to include Treatment-Naïve Genotype 3 patients with compensated cirrhosis. "AbbVie is committed to eliminating hepatitis C by 2030 and sees this objective as a national public health... |
24,332 | 2020-11-09 00:00:00 UTC | Merck Stock Poised For 25% Gains | ABBV | https://www.nasdaq.com/articles/merck-stock-poised-for-25-gains-2020-11-09 | null | null | Merck’s stock (NYSE: MRK) lost more than 28% – dropping from $92 at the beginning of the year to $66 in late March – then jumped 21% to around $80 now. That means it has partially recovered to the levels where it started the year. That said, MRK stock has underperformed the broader markets, with the S&P 500 which fell ... | Currently, AbbVie’s Humira is the largest selling drug across the globe with roughly $20 billion in annual sales, but it will face patent expiry in 2023. This can be attributed to 30% growth in Keytruda sales, which offset the decline seen in some of the company’s other drugs and vaccines, as people avoided visiting ho... | Currently, AbbVie’s Humira is the largest selling drug across the globe with roughly $20 billion in annual sales, but it will face patent expiry in 2023. Merck now expects revenues of $47.6 billion to $48.6 billion for the full year 2020, assuming $2.35 billion of Covid headwind for the year. Despite the recent underpe... | Currently, AbbVie’s Humira is the largest selling drug across the globe with roughly $20 billion in annual sales, but it will face patent expiry in 2023. Merck now expects revenues of $47.6 billion to $48.6 billion for the full year 2020, assuming $2.35 billion of Covid headwind for the year. Despite the recent underpe... | Currently, AbbVie’s Humira is the largest selling drug across the globe with roughly $20 billion in annual sales, but it will face patent expiry in 2023. Despite the recent underperformance and the impact of the current pandemic, Trefis estimates Merck’s Valuation at about $102 per share, roughly 27% above the current ... |
24,333 | 2020-11-03 00:00:00 UTC | 3 ‘Strong Buy’ Stocks With at Least 5% Dividend Yield | ABBV | https://www.nasdaq.com/articles/3-strong-buy-stocks-with-at-least-5-dividend-yield-2020-11-03 | null | null | Americans went to the polls today under the shadow of a resurging pandemic, with a substantial increase in cases nationwide and the number of people hospitalized with COVID-19 reaching record highs in a growing number of states. Meanwhile, it's still unclear what a second stimulus package from the federal government ma... | AbbVie (ABBV) AbbVie is a pharmaceutical company, one of Big Pharma’s major names. Humira is expected to bring in ~40% of AbbVie’s 2020 drug division revenues – but with an expired patent, competition is growing. Against this backdrop, AbbVie had acquired another pharmaceutical company, Allergan, that increased top-lin... | AbbVie (ABBV) AbbVie is a pharmaceutical company, one of Big Pharma’s major names. Humira is expected to bring in ~40% of AbbVie’s 2020 drug division revenues – but with an expired patent, competition is growing. Against this backdrop, AbbVie had acquired another pharmaceutical company, Allergan, that increased top-lin... | Covering the stock for SVB Leerink, analyst Geoff Porges noted, "AbbVie had another strong beat and raise in Q3, demonstrating their very resilient business during the pandemic and highlighting strong growth prospects for their core business. Guidance was once again raised, and the company’s comments about mid- to long... | To this end, Porges rates AbbVie an Outperform (i.e. Buy) along with a $119 price target. AbbVie (ABBV) AbbVie is a pharmaceutical company, one of Big Pharma’s major names. Humira is expected to bring in ~40% of AbbVie’s 2020 drug division revenues – but with an expired patent, competition is growing. |
24,334 | 2020-11-02 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Honeywell, Roku, Nielsen, Jounce, Twitter | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-honeywell-roku-nielsen-jounce-twitter-2020-11-02 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's major indexes bounced back on Monday after their steepest weekly loss since March as investors geared up for an event-packed week centered aro... | The top three S&P 500 .PG.INX percentage gainers: ** Nielsen Holdings NLSN.N, up 7.6% ** Mohawk Industries MHK.N, up 7.4% ** Newell Brand Inc NWL.O, up 5.8% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line NCLH.N, down 5.8% ** Southwest Airlines LUV.N, down 2.9% ** Henry Schein HSIC.O, down 2.8... | The top three S&P 500 .PG.INX percentage gainers: ** Nielsen Holdings NLSN.N, up 7.6% ** Mohawk Industries MHK.N, up 7.4% ** Newell Brand Inc NWL.O, up 5.8% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line NCLH.N, down 5.8% ** Southwest Airlines LUV.N, down 2.9% ** Henry Schein HSIC.O, down 2.8... | The top three S&P 500 .PG.INX percentage gainers: ** Nielsen Holdings NLSN.N, up 7.6% ** Mohawk Industries MHK.N, up 7.4% ** Newell Brand Inc NWL.O, up 5.8% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line NCLH.N, down 5.8% ** Southwest Airlines LUV.N, down 2.9% ** Henry Schein HSIC.O, down 2.8... | The top three S&P 500 .PG.INX percentage gainers: ** Nielsen Holdings NLSN.N, up 7.6% ** Mohawk Industries MHK.N, up 7.4% ** Newell Brand Inc NWL.O, up 5.8% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line NCLH.N, down 5.8% ** Southwest Airlines LUV.N, down 2.9% ** Henry Schein HSIC.O, down 2.8... |
24,335 | 2020-11-02 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Nio, Norwegian Cruise, Fisker, Twitter, AngloGold Ashanti | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-nio-norwegian-cruise-fisker-twitter-anglogold-ashanti-2020-11 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's major indexes gained ground on Monday after suffering their worst week since March, as investors geared up for an event-packed week centered a... | The top three S&P 500 .PG.INX percentage gainers: ** Mohawk Industries MHK.N, up 10.4% ** Newell Brand NWL.O, up 7% ** Tapestry Inc TPR.N, up 6.8% The top three S&P 500 .PL.INX percentage losers: ** Twitter Inc TWTR.N, down 5% ** Incyte Corp INCY.OQ, down 4.1% ** Norwegian Cruise Line NCLH.N, down 4% The top three NYSE... | The top three S&P 500 .PG.INX percentage gainers: ** Mohawk Industries MHK.N, up 10.4% ** Newell Brand NWL.O, up 7% ** Tapestry Inc TPR.N, up 6.8% The top three S&P 500 .PL.INX percentage losers: ** Twitter Inc TWTR.N, down 5% ** Incyte Corp INCY.OQ, down 4.1% ** Norwegian Cruise Line NCLH.N, down 4% The top three NYSE... | The top three S&P 500 .PG.INX percentage gainers: ** Mohawk Industries MHK.N, up 10.4% ** Newell Brand NWL.O, up 7% ** Tapestry Inc TPR.N, up 6.8% The top three S&P 500 .PL.INX percentage losers: ** Twitter Inc TWTR.N, down 5% ** Incyte Corp INCY.OQ, down 4.1% ** Norwegian Cruise Line NCLH.N, down 4% The top three NYSE... | The top three S&P 500 .PG.INX percentage gainers: ** Mohawk Industries MHK.N, up 10.4% ** Newell Brand NWL.O, up 7% ** Tapestry Inc TPR.N, up 6.8% The top three S&P 500 .PL.INX percentage losers: ** Twitter Inc TWTR.N, down 5% ** Incyte Corp INCY.OQ, down 4.1% ** Norwegian Cruise Line NCLH.N, down 4% The top three NYSE... |
24,336 | 2020-11-02 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Nio, Dunkin' Brands, Honeywell, Jounce | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-nio-dunkin-brands-honeywell-jounce-2020-11-02 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's major indexes bounced back on Monday after their steepest weekly loss since March, as investors geared up for an event-packed week centered ar... | $5 per share - Cantor ** Clorox CLX.N: up 4.8% BUZZ-Clorox gains after lifting sales, profit forecasts ** Regis Corp RGS.N: down 4.9% BUZZ-Set to open at over 1-month low after sales slump 55% ** Fusion Pharma FUSN.O: up 6.0% BUZZ-Up on AstraZeneca partnership to develop cancer therapies ** Camping World CWH.N: up 12.6... | $5 per share - Cantor ** Clorox CLX.N: up 4.8% BUZZ-Clorox gains after lifting sales, profit forecasts ** Regis Corp RGS.N: down 4.9% BUZZ-Set to open at over 1-month low after sales slump 55% ** Fusion Pharma FUSN.O: up 6.0% BUZZ-Up on AstraZeneca partnership to develop cancer therapies ** Camping World CWH.N: up 12.6... | $5 per share - Cantor ** Clorox CLX.N: up 4.8% BUZZ-Clorox gains after lifting sales, profit forecasts ** Regis Corp RGS.N: down 4.9% BUZZ-Set to open at over 1-month low after sales slump 55% ** Fusion Pharma FUSN.O: up 6.0% BUZZ-Up on AstraZeneca partnership to develop cancer therapies ** Camping World CWH.N: up 12.6... | $5 per share - Cantor ** Clorox CLX.N: up 4.8% BUZZ-Clorox gains after lifting sales, profit forecasts ** Regis Corp RGS.N: down 4.9% BUZZ-Set to open at over 1-month low after sales slump 55% ** Fusion Pharma FUSN.O: up 6.0% BUZZ-Up on AstraZeneca partnership to develop cancer therapies ** Camping World CWH.N: up 12.6... |
24,337 | 2020-11-02 00:00:00 UTC | 3 Top Stocks With High Dividend Yields | ABBV | https://www.nasdaq.com/articles/3-top-stocks-with-high-dividend-yields-2020-11-02 | null | null | Picking a high-paying dividend stock to buy is easy. The hard part is finding an income investment where the dividend isn't at risk, that isn't a value trap about to plummet in share price, or that's overvalued. Verizon Communications (NYSE: VZ), AbbVie (NYSE: ABBV), and B&G Foods (NYSE: BGS) all have safe and reliable... | AbbVie's P/E of 18.14 is dwarfed by the P/E of competitors Gilead Sciences (NASDAQ: GILD) at 59.97 and Bristol Myers Squibb (NYSE: BMY) at 71.36. Verizon Communications (NYSE: VZ), AbbVie (NYSE: ABBV), and B&G Foods (NYSE: BGS) all have safe and reliable dividends that pay 4% or more. Shares of Verizon and AbbVie are b... | Verizon Communications (NYSE: VZ), AbbVie (NYSE: ABBV), and B&G Foods (NYSE: BGS) all have safe and reliable dividends that pay 4% or more. VZ Return on Equity data by YCharts AbbVie remains a great dividend AbbVie's share price is down 3.7% this year, which offers another opportunity and drives up the yield on the com... | VZ Return on Equity data by YCharts AbbVie remains a great dividend AbbVie's share price is down 3.7% this year, which offers another opportunity and drives up the yield on the company's dividend to 5.85%. Verizon Communications (NYSE: VZ), AbbVie (NYSE: ABBV), and B&G Foods (NYSE: BGS) all have safe and reliable divid... | VZ Return on Equity data by YCharts AbbVie remains a great dividend AbbVie's share price is down 3.7% this year, which offers another opportunity and drives up the yield on the company's dividend to 5.85%. Verizon Communications (NYSE: VZ), AbbVie (NYSE: ABBV), and B&G Foods (NYSE: BGS) all have safe and reliable divid... |
24,338 | 2020-11-02 00:00:00 UTC | 3 Dividend Stocks to Supplement Your Social Security | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-supplement-your-social-security-2020-11-02 | null | null | In order to have peace of mind in retirement, people need to know that they will have enough cash coming in every month to pay the bills. Now, Social Security may serve as the foundation of that retirement income structure, but your benefit checks will only replace about 40% of your pre-retirement income. Where are you... | There are many more products in AbbVie's pipeline now, so retirees can sit back and enjoy that huge dividend while waiting for Allergan to be fully integrated into its new owner's operation. A mouthwatering dividend If you're looking for nice, juicy dividends, AbbVie (NYSE: ABBV) is worth a gander. However, in 2019, Ab... | A mouthwatering dividend If you're looking for nice, juicy dividends, AbbVie (NYSE: ABBV) is worth a gander. However, in 2019, AbbVie bought Allergan, which makes eye-care products as well as Botox, and the revenues from this new acquisition will hopefully replace some of the sales of Humira that are being lost to gene... | See the 10 stocks *Stock Advisor returns as of October 20, 2020 Barbara Eisner Bayer owns shares of AbbVie and Waste Management. A mouthwatering dividend If you're looking for nice, juicy dividends, AbbVie (NYSE: ABBV) is worth a gander. However, in 2019, AbbVie bought Allergan, which makes eye-care products as well as... | See the 10 stocks *Stock Advisor returns as of October 20, 2020 Barbara Eisner Bayer owns shares of AbbVie and Waste Management. A mouthwatering dividend If you're looking for nice, juicy dividends, AbbVie (NYSE: ABBV) is worth a gander. However, in 2019, AbbVie bought Allergan, which makes eye-care products as well as... |
24,339 | 2020-11-02 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Nio, Nielsen, Jounce, Dunkin' Brands, Superior Industries | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-nio-nielsen-jounce-dunkin-brands-superior-industries-2020-11 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's major indexes were set to bounce back on Monday after their steepest weekly loss since March as investors geared up for an event-packed week c... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Superior Industries SUP.N, up 30.9% ** VirnetX Holding Corp VHC.N, up 13.7% ** Cohen & Steers MLP MIE.N, up 12.6% The top three NYSE percentage losers premarket .PRPL.NQ: ** CBL & Associates Properties CBL.N, down 22% ** Pennsylvania Real Estate Investment Tr... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Superior Industries SUP.N, up 30.9% ** VirnetX Holding Corp VHC.N, up 13.7% ** Cohen & Steers MLP MIE.N, up 12.6% The top three NYSE percentage losers premarket .PRPL.NQ: ** CBL & Associates Properties CBL.N, down 22% ** Pennsylvania Real Estate Investment Tr... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Superior Industries SUP.N, up 30.9% ** VirnetX Holding Corp VHC.N, up 13.7% ** Cohen & Steers MLP MIE.N, up 12.6% The top three NYSE percentage losers premarket .PRPL.NQ: ** CBL & Associates Properties CBL.N, down 22% ** Pennsylvania Real Estate Investment Tr... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Superior Industries SUP.N, up 30.9% ** VirnetX Holding Corp VHC.N, up 13.7% ** Cohen & Steers MLP MIE.N, up 12.6% The top three NYSE percentage losers premarket .PRPL.NQ: ** CBL & Associates Properties CBL.N, down 22% ** Pennsylvania Real Estate Investment Tr... |
24,340 | 2020-10-31 00:00:00 UTC | Is Drug Pricing Backlash a Serious Risk for Big Pharma Stocks? | ABBV | https://www.nasdaq.com/articles/is-drug-pricing-backlash-a-serious-risk-for-big-pharma-stocks-2020-10-31 | null | null | Drugs in the U.S. are estimated to cost around 56% more on average than in similarly industrialized countries, and Americans are fed up. With prices for life-saving medications rising consistently, it's no surprise that people are irate and desperate for change. But should investors fear that public backlash will harm ... | The report found that repeated price increases for Amgen's drug Enbrel were the result of a tit-for-tat strategy to maintain price parity with AbbVie's (NYSE: ABBV) drug Humira. At the end of September, the U.S. House of Representatives held hearings with testimonies from the CEOs of major pharmaceutical companies, inc... | The report found that repeated price increases for Amgen's drug Enbrel were the result of a tit-for-tat strategy to maintain price parity with AbbVie's (NYSE: ABBV) drug Humira. At the end of September, the U.S. House of Representatives held hearings with testimonies from the CEOs of major pharmaceutical companies, inc... | The report found that repeated price increases for Amgen's drug Enbrel were the result of a tit-for-tat strategy to maintain price parity with AbbVie's (NYSE: ABBV) drug Humira. The sole way that backlash over drug prices would dent pharma stock prices is from policy change, whether it's through new laws or changes to ... | The report found that repeated price increases for Amgen's drug Enbrel were the result of a tit-for-tat strategy to maintain price parity with AbbVie's (NYSE: ABBV) drug Humira. Instead, the Congressional report alleges that raising Revlimid's price was solely a function of increasing the drug's profitability. The orde... |
24,341 | 2020-10-31 00:00:00 UTC | 5 No-Brainer Stocks to Buy if Donald Trump Wins in November | ABBV | https://www.nasdaq.com/articles/5-no-brainer-stocks-to-buy-if-donald-trump-wins-in-november-2020-10-31 | null | null | Talking heads get paid to speculate about what the market will do in different scenarios, but it is rare that anyone can truly know how a particular company, industry, or the overall market will fare based on a presidential election. That said, a reelection of a U.S. President offers more certainty, because policies th... | Let's see why Zoom Video (NASDAQ: ZM), Chevron Corporation (NYSE: CVX), Deere & Company (NYSE: DE), Bank OZK (NASDAQ: OZK), and AbbVie (NYSE: ABBV) are poised to benefit. AbbVie AbbVie is the maker of the world's best-selling drug. If the President loses in November, the policies will almost certainly take on the prici... | Let's see why Zoom Video (NASDAQ: ZM), Chevron Corporation (NYSE: CVX), Deere & Company (NYSE: DE), Bank OZK (NASDAQ: OZK), and AbbVie (NYSE: ABBV) are poised to benefit. AbbVie AbbVie is the maker of the world's best-selling drug. If the President loses in November, the policies will almost certainly take on the prici... | Let's see why Zoom Video (NASDAQ: ZM), Chevron Corporation (NYSE: CVX), Deere & Company (NYSE: DE), Bank OZK (NASDAQ: OZK), and AbbVie (NYSE: ABBV) are poised to benefit. AbbVie AbbVie is the maker of the world's best-selling drug. If the President loses in November, the policies will almost certainly take on the prici... | Let's see why Zoom Video (NASDAQ: ZM), Chevron Corporation (NYSE: CVX), Deere & Company (NYSE: DE), Bank OZK (NASDAQ: OZK), and AbbVie (NYSE: ABBV) are poised to benefit. AbbVie AbbVie is the maker of the world's best-selling drug. If the President loses in November, the policies will almost certainly take on the prici... |
24,342 | 2020-10-31 00:00:00 UTC | AbbVie (ABBV) Q3 2020 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q3-2020-earnings-call-transcript-2020-10-31 | null | null | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q3 2020 Earnings Call
Oct 30, 2020, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning. And thank you for standing by. Welcome to AbbVie's third-quarter 2020earnings conference call [Operator instruc... | AbbVie (NYSE: ABBV) Q3 2020 Earnings Call Oct 30, 2020, 9:00 a.m. Welcome to AbbVie's third-quarter 2020earnings conference call [Operator instructions] I would like to introduce Ms. Liz Shea, vice president of investor relations. AbbVie cautions that these forward-looking statements are subject to risks and uncertaint... | Operator [Operator signoff] Duration: 89 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the board and Chief Executive Officer Mike Severino -- Vice Chairman and President Rob Michael -- Executive Vice President and Chief Financial Officer Chris Schott -- J.P. Mo... | Operator [Operator signoff] Duration: 89 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the board and Chief Executive Officer Mike Severino -- Vice Chairman and President Rob Michael -- Executive Vice President and Chief Financial Officer Chris Schott -- J.P. Mo... | Operator [Operator signoff] Duration: 89 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the board and Chief Executive Officer Mike Severino -- Vice Chairman and President Rob Michael -- Executive Vice President and Chief Financial Officer Chris Schott -- J.P. Mo... |
24,343 | 2020-10-30 00:00:00 UTC | US STOCKS-Tech slide hits Wall St as coronavirus cases spiral | ABBV | https://www.nasdaq.com/articles/us-stocks-tech-slide-hits-wall-st-as-coronavirus-cases-spiral-2020-10-30 | null | null | By Medha Singh and Shivani Kumaresan
Oct 30 (Reuters) - Wall Street's major indexes tumbled on Friday, dragged down by a slide in shares of tech heavyweights following their quarterly results, with a record rise in coronavirus cases and nerves over the presidential election adding to a downbeat mood.
The three main ind... | AbbVie Inc ABBV.N gained 4.3% after the drugmaker raised its full-year profit forecast, bolstered by signs of recovery in demand for its Botox injection. By Medha Singh and Shivani Kumaresan Oct 30 (Reuters) - Wall Street's major indexes tumbled on Friday, dragged down by a slide in shares of tech heavyweights followin... | AbbVie Inc ABBV.N gained 4.3% after the drugmaker raised its full-year profit forecast, bolstered by signs of recovery in demand for its Botox injection. ET the Dow Jones Industrial Average .DJI fell 239.82 points, or 0.90% to 26,419.29, the S&P 500 .SPX lost 41.73 points, or 1.26% to 3,268.38 and the Nasdaq Composite ... | AbbVie Inc ABBV.N gained 4.3% after the drugmaker raised its full-year profit forecast, bolstered by signs of recovery in demand for its Botox injection. By Medha Singh and Shivani Kumaresan Oct 30 (Reuters) - Wall Street's major indexes tumbled on Friday, dragged down by a slide in shares of tech heavyweights followin... | AbbVie Inc ABBV.N gained 4.3% after the drugmaker raised its full-year profit forecast, bolstered by signs of recovery in demand for its Botox injection. The CBOE volatility index .VIX held at a 20-week high ahead of the final weekend before Election Day on Tuesday. Apple Inc AAPL.O tumbled about 5.5% after it posted t... |
24,344 | 2020-10-30 00:00:00 UTC | AbbVie Raises FY20 Adj. EPS Outlook; Boosts Dividend 10.2% - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie-raises-fy20-adj.-eps-outlook-boosts-dividend-10.2-quick-facts-2020-10-30 | null | null | (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2020.
For fiscal 2020, AbbVie now projects adjusted earnings in a range of $10.47 to $10.49 per share, up from the prior guidance range of $... | (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2020. Further, AbbVie announced that its board of directors declared a 10.2 percent higher quarterly cash dividend of $1.30 per share, begin... | (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2020. For fiscal 2020, AbbVie now projects adjusted earnings in a range of $10.47 to $10.49 per share, up from the prior guidance range of $... | (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2020. For fiscal 2020, AbbVie now projects adjusted earnings in a range of $10.47 to $10.49 per share, up from the prior guidance range of $... | (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2020. Further, AbbVie announced that its board of directors declared a 10.2 percent higher quarterly cash dividend of $1.30 per share, begin... |
24,345 | 2020-10-30 00:00:00 UTC | How AbbVie Beat Expectations in Q3 | ABBV | https://www.nasdaq.com/articles/how-abbvie-beat-expectations-in-q3-2020-10-30 | null | null | AbbVie (NYSE: ABBV) hasn't exactly given investors a lot to get excited about so far in 2020. As of Thursday's close, its shares were down by 9% year to date, lagging well behind the S&P 500 index's performance.
However, the big drugmaker's shareholders now have a reason for at least some enthusiasm. AbbVie reported it... | AbbVie announced one more piece of positive news for investors: The company's status as a Dividend Aristocrat appears to be rock-solid. AbbVie (NYSE: ABBV) hasn't exactly given investors a lot to get excited about so far in 2020. AbbVie reported its third-quarter results before the market opened on Friday. | In the prior-year period, AbbVie generated GAAP earnings of $1.9 billion, or $1.26 per share. AbbVie (NYSE: ABBV) hasn't exactly given investors a lot to get excited about so far in 2020. AbbVie reported its third-quarter results before the market opened on Friday. | By the numbers AbbVie announced Q3 revenue of $12.9 billion, a 52% jump from the $8.5 billion reported in the same quarter of the previous year. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Keith Speights owns shares of AbbVie. AbbVie (NYSE: ABBV) hasn't exactly given investors a lot to get excited a... | By the numbers AbbVie announced Q3 revenue of $12.9 billion, a 52% jump from the $8.5 billion reported in the same quarter of the previous year. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie (NYSE: ABBV) hasn't exactly giv... |
24,346 | 2020-10-30 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-BioLine RX, Pitney Bowes, Atea Pharma | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-bioline-rx-pitney-bowes-atea-pharma-2020-10-30 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's major indexes tumbled on Friday, dragged down by a slide in shares of tech heavyweights following their quarterly results, with a record rise ... | The top three S&P 500 .PG.INX percentage gainers: ** Mohawk Industries Inc , up 9.2% ** ResMed Inc , up 6.1% ** Charter Communications Inc , up 4.7% The top three S&P 500 .PL.INX percentage losers: ** Twitter Inc , down 19.8% ** Western Union Co , down 7.8% ** Etsy Inc , down 7.1% The top NYSE .PG.N percentage gainers:... | The top three S&P 500 .PG.INX percentage gainers: ** Mohawk Industries Inc , up 9.2% ** ResMed Inc , up 6.1% ** Charter Communications Inc , up 4.7% The top three S&P 500 .PL.INX percentage losers: ** Twitter Inc , down 19.8% ** Western Union Co , down 7.8% ** Etsy Inc , down 7.1% The top NYSE .PG.N percentage gainers:... | The top three S&P 500 .PG.INX percentage gainers: ** Mohawk Industries Inc , up 9.2% ** ResMed Inc , up 6.1% ** Charter Communications Inc , up 4.7% The top three S&P 500 .PL.INX percentage losers: ** Twitter Inc , down 19.8% ** Western Union Co , down 7.8% ** Etsy Inc , down 7.1% The top NYSE .PG.N percentage gainers:... | The top three S&P 500 .PG.INX percentage gainers: ** Mohawk Industries Inc , up 9.2% ** ResMed Inc , up 6.1% ** Charter Communications Inc , up 4.7% The top three S&P 500 .PL.INX percentage losers: ** Twitter Inc , down 19.8% ** Western Union Co , down 7.8% ** Etsy Inc , down 7.1% The top NYSE .PG.N percentage gainers:... |
24,347 | 2020-10-30 00:00:00 UTC | US STOCKS-Wall St slumps as tech stocks slide, COVID cases jump | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-st-slumps-as-tech-stocks-slide-covid-cases-jump-2020-10-30 | null | null | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
Twitter slumps as user growth disappoints
Under Armour climbs as revenue forecast exceeds expectations
Apple, Amazon, Facebook drop after results
Alphabet rises as businesses resume ad spending
Indexes down: Dow 0... | AbbVie Inc ABBV.N gained 5% after the drugmaker posted better-than-expected quarterly earnings and raised its full-year adjusted profit forecast. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Twitter slumps as user growth disappoints Under Armour climbs as re... | AbbVie Inc ABBV.N gained 5% after the drugmaker posted better-than-expected quarterly earnings and raised its full-year adjusted profit forecast. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Twitter slumps as user growth disappoints Under Armour climbs as re... | AbbVie Inc ABBV.N gained 5% after the drugmaker posted better-than-expected quarterly earnings and raised its full-year adjusted profit forecast. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Twitter slumps as user growth disappoints Under Armour climbs as re... | AbbVie Inc ABBV.N gained 5% after the drugmaker posted better-than-expected quarterly earnings and raised its full-year adjusted profit forecast. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Twitter slumps as user growth disappoints Under Armour climbs as re... |
24,348 | 2020-10-30 00:00:00 UTC | US STOCKS-Tech stocks knock down Wall St as coronavirus cases spiral | ABBV | https://www.nasdaq.com/articles/us-stocks-tech-stocks-knock-down-wall-st-as-coronavirus-cases-spiral-2020-10-30 | null | null | By Medha Singh and Shivani Kumaresan
Oct 30 (Reuters) - Wall Street's major indexes tumbled on Friday, dragged down by a slide in shares of tech heavyweights following their quarterly results, with a record rise in coronavirus cases and nerves over the presidential election adding to a downbeat mood.
The three main ind... | AbbVie Inc ABBV.N gained 5% after the drugmaker posted better-than-expected quarterly earnings and raised its full-year adjusted profit forecast. By Medha Singh and Shivani Kumaresan Oct 30 (Reuters) - Wall Street's major indexes tumbled on Friday, dragged down by a slide in shares of tech heavyweights following their ... | AbbVie Inc ABBV.N gained 5% after the drugmaker posted better-than-expected quarterly earnings and raised its full-year adjusted profit forecast. ET the Dow Jones Industrial Average .DJI fell 423.74 points, or 1.58%, to 26,237.80, the S&P 500 .SPX lost 59.85 points, or 1.81%, to 3,250.76 and the Nasdaq Composite .IXIC ... | AbbVie Inc ABBV.N gained 5% after the drugmaker posted better-than-expected quarterly earnings and raised its full-year adjusted profit forecast. By Medha Singh and Shivani Kumaresan Oct 30 (Reuters) - Wall Street's major indexes tumbled on Friday, dragged down by a slide in shares of tech heavyweights following their ... | AbbVie Inc ABBV.N gained 5% after the drugmaker posted better-than-expected quarterly earnings and raised its full-year adjusted profit forecast. By Medha Singh and Shivani Kumaresan Oct 30 (Reuters) - Wall Street's major indexes tumbled on Friday, dragged down by a slide in shares of tech heavyweights following their ... |
24,349 | 2020-10-30 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-BioLine RX, Axovant, Bellicum Pharma | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-bioline-rx-axovant-bellicum-pharma-2020-10-30 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street was set to tumble again on Friday, triggered by a selloff in tech heavyweights following their underwhelming business updates, with a record ris... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Mohawk Industries Inc MHK.N, up 15.5% ** Plantronics Inc PLT.N, up 14.3% ** Essex Property Trust Inc ESS.N, up 11.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Ryerson Holding Corp RYI.N, down 22.9% ** Hexo Corp HEXO.N, down 18% ** Twitter In... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Mohawk Industries Inc MHK.N, up 15.5% ** Plantronics Inc PLT.N, up 14.3% ** Essex Property Trust Inc ESS.N, up 11.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Ryerson Holding Corp RYI.N, down 22.9% ** Hexo Corp HEXO.N, down 18% ** Twitter In... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Mohawk Industries Inc MHK.N, up 15.5% ** Plantronics Inc PLT.N, up 14.3% ** Essex Property Trust Inc ESS.N, up 11.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Ryerson Holding Corp RYI.N, down 22.9% ** Hexo Corp HEXO.N, down 18% ** Twitter In... | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Mohawk Industries Inc MHK.N, up 15.5% ** Plantronics Inc PLT.N, up 14.3% ** Essex Property Trust Inc ESS.N, up 11.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Ryerson Holding Corp RYI.N, down 22.9% ** Hexo Corp HEXO.N, down 18% ** Twitter In... |
24,350 | 2020-10-30 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-BioLine RX, Bellicum Pharma, Mohawk Industries | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-bioline-rx-bellicum-pharma-mohawk-industries-2020-10-30 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes fell at the open on Friday triggered by a selloff in tech heavyweights following their underwhelming business updates, with a rec... | The top three S&P 500 .PG.INX percentage gainers: ** Mohawk Industries Inc , up 12.5% ** ResMed Inc , up 8.1% ** Newell Brands Inc , up 7.4% The top three S&P 500 .PL.INX percentage losers: ** Twitter Inc , down 16.8% ** MGM Resorts International , down 7.1% ** Fortinet Inc , down 7% The top three NYSE .PG.N percentage... | The top three S&P 500 .PG.INX percentage gainers: ** Mohawk Industries Inc , up 12.5% ** ResMed Inc , up 8.1% ** Newell Brands Inc , up 7.4% The top three S&P 500 .PL.INX percentage losers: ** Twitter Inc , down 16.8% ** MGM Resorts International , down 7.1% ** Fortinet Inc , down 7% The top three NYSE .PG.N percentage... | The top three S&P 500 .PG.INX percentage gainers: ** Mohawk Industries Inc , up 12.5% ** ResMed Inc , up 8.1% ** Newell Brands Inc , up 7.4% The top three S&P 500 .PL.INX percentage losers: ** Twitter Inc , down 16.8% ** MGM Resorts International , down 7.1% ** Fortinet Inc , down 7% The top three NYSE .PG.N percentage... | The top three S&P 500 .PG.INX percentage gainers: ** Mohawk Industries Inc , up 12.5% ** ResMed Inc , up 8.1% ** Newell Brands Inc , up 7.4% The top three S&P 500 .PL.INX percentage losers: ** Twitter Inc , down 16.8% ** MGM Resorts International , down 7.1% ** Fortinet Inc , down 7% The top three NYSE .PG.N percentage... |
24,351 | 2020-10-30 00:00:00 UTC | 2 No-Brainer Dividend Stocks Yielding More Than 4% | ABBV | https://www.nasdaq.com/articles/2-no-brainer-dividend-stocks-yielding-more-than-4-2020-10-30 | null | null | For dividend-seeking investors, looking at a stock's yield is important. High yields tend to be more attractive than low yields if all other things remain equal. But in real life, things are rarely equal, so before purchasing shares of a company because of its dividend, it's essential to look beyond how much it dividen... | In that spirit, here are two dividend stocks worth buying today: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). The low cash-payout ratio is a good indication that AbbVie can sustain dividend increases, so long as the company continues delivering strong financial results. At any rate, AbbVie is recouping some ... | In that spirit, here are two dividend stocks worth buying today: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). Let's look closer into why AbbVie and Gilead Sciences are great picks for income-seeking investors. ABBV data by YCharts 1. | In that spirit, here are two dividend stocks worth buying today: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). According to AbbVie CEO Richard A. Gonzalez, "We remain confident that the AbbVie Allergan combination will generate significant cash flows, which will support our strong and growing dividend and rap... | AbbVie Dividend investors will find what they're looking for in AbbVie. In that spirit, here are two dividend stocks worth buying today: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). Let's look closer into why AbbVie and Gilead Sciences are great picks for income-seeking investors. |
24,352 | 2020-10-30 00:00:00 UTC | AbbVie Q3 adjusted earnings Beat Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-q3-adjusted-earnings-beat-estimates-2020-10-30 | null | null | (RTTNews) - AbbVie (ABBV) released earnings for its third quarter that rose from last year.
The company's bottom line totaled $2.31 billion, or $1.29 per share. This compares with $1.88 billion, or $1.26 per share, in last year's third quarter.
Excluding items, AbbVie reported adjusted earnings of $5.05 billion or $2.8... | (RTTNews) - AbbVie (ABBV) released earnings for its third quarter that rose from last year. Excluding items, AbbVie reported adjusted earnings of $5.05 billion or $2.83 per share for the period. AbbVie earnings at a glance: -Earnings (Q3): $5.05 Bln. | Excluding items, AbbVie reported adjusted earnings of $5.05 billion or $2.83 per share for the period. (RTTNews) - AbbVie (ABBV) released earnings for its third quarter that rose from last year. AbbVie earnings at a glance: -Earnings (Q3): $5.05 Bln. | (RTTNews) - AbbVie (ABBV) released earnings for its third quarter that rose from last year. Excluding items, AbbVie reported adjusted earnings of $5.05 billion or $2.83 per share for the period. AbbVie earnings at a glance: -Earnings (Q3): $5.05 Bln. | (RTTNews) - AbbVie (ABBV) released earnings for its third quarter that rose from last year. Excluding items, AbbVie reported adjusted earnings of $5.05 billion or $2.83 per share for the period. AbbVie earnings at a glance: -Earnings (Q3): $5.05 Bln. |
24,353 | 2020-10-30 00:00:00 UTC | AbbVie raises 2020 profit forecast as COVID-19 hit eases | ABBV | https://www.nasdaq.com/articles/abbvie-raises-2020-profit-forecast-as-covid-19-hit-eases-2020-10-30-0 | null | null | Adds share movement, compares profit with estimates
Oct 30 (Reuters) - Drugmaker AbbVie Inc ABBV.N posted better-than-expected quarterly earnings and raised its full-year adjusted profit forecast on Friday, as demand for its Botox and other treatments showed signs of recovery from the COVID-19 pandemic hit.
Lockdowns a... | Botox, which AbbVie gained through its $64 billion acquisition of Allergan in May, suffered an initial hit during the peak of the health crisis, but demand has since improved. AbbVie's portfolio of aesthetic medicines such as Botox was showing a "V-shaped recovery," Chief Executive Officer Richard Gonzalez said in a st... | Humira brought in sales of $5.14 billion and AbbVie's newer psoriasis medicine Skyrizi generated $435 million in the quarter ended Sept. 30. AbbVie forecast a combined company 2020 adjusted earnings of $10.47 to $10.49 per share, compared with $10.35 to $10.45 per share forecast earlier. Excluding items, AbbVie earned ... | Adds share movement, compares profit with estimates Oct 30 (Reuters) - Drugmaker AbbVie Inc ABBV.N posted better-than-expected quarterly earnings and raised its full-year adjusted profit forecast on Friday, as demand for its Botox and other treatments showed signs of recovery from the COVID-19 pandemic hit. AbbVie fore... | Adds share movement, compares profit with estimates Oct 30 (Reuters) - Drugmaker AbbVie Inc ABBV.N posted better-than-expected quarterly earnings and raised its full-year adjusted profit forecast on Friday, as demand for its Botox and other treatments showed signs of recovery from the COVID-19 pandemic hit. Excluding i... |
24,354 | 2020-10-29 00:00:00 UTC | Pre-Market Earnings Report for October 30, 2020 : ABBV, XOM, CVX, CHTR, HON, MO, CL, AON, LHX, PEG, LYB, WY | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-october-30-2020-%3A-abbv-xom-cvx-chtr-hon-mo-cl-aon-lhx-peg | null | null | The following companies are expected to report earnings prior to market open on 10/30/2020. Visit our Earnings Calendar for a full list of expected earnings releases.
AbbVie Inc. (ABBV) is reporting for the quarter ending September 30, 2020. The large cap pharmaceutical company's consensus earnings per share forecast ... | AbbVie Inc. (ABBV) is reporting for the quarter ending September 30, 2020. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 7.72 vs. an industry ratio of 13.50. | AbbVie Inc. (ABBV) is reporting for the quarter ending September 30, 2020. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 7.72 vs. an industry ratio of 13.50. | AbbVie Inc. (ABBV) is reporting for the quarter ending September 30, 2020. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 7.72 vs. an industry ratio of 13.50. | In the past year ABBV has beat the expectations every quarter. AbbVie Inc. (ABBV) is reporting for the quarter ending September 30, 2020. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 7.72 vs. an industry ratio of 13.50. |
24,355 | 2020-10-29 00:00:00 UTC | 2 Healthcare Dividend Stocks to Buy No Matter Who Wins the Election | ABBV | https://www.nasdaq.com/articles/2-healthcare-dividend-stocks-to-buy-no-matter-who-wins-the-election-2020-10-29 | null | null | Many risk-averse investors, like retirees, buy dividend-paying stocks for their regular distribution of cash to shareholders. Dividends are not guaranteed, and management can cut them at any time, so it's important to understand how safe the dividend is when analyzing a company. Many times, the higher the yield, the ri... | Abbott Labs spun off its branded pharmaceutical business as AbbVie (NYSE: ABBV) in 2013. Gross margin and operating margin have remained largely unchanged in the time since the AbbVie spinoff. ABT Cash Dividend Payout Ratio (Annual) data by YCharts Having a diverse product offering in a demographically advantaged indus... | Abbott Labs spun off its branded pharmaceutical business as AbbVie (NYSE: ABBV) in 2013. Gross margin and operating margin have remained largely unchanged in the time since the AbbVie spinoff. In 2015, it purchased CareFusion for $12.5 billion, bringing medication management and patient safety solutions into the fold. | Abbott Labs spun off its branded pharmaceutical business as AbbVie (NYSE: ABBV) in 2013. Gross margin and operating margin have remained largely unchanged in the time since the AbbVie spinoff. Abbott Labs Abbott Labs is a diversified healthcare company comprised of four business units: medical devices, diagnostics, est... | Abbott Labs spun off its branded pharmaceutical business as AbbVie (NYSE: ABBV) in 2013. Gross margin and operating margin have remained largely unchanged in the time since the AbbVie spinoff. That's why I like to look at the ratio of the dividends paid to free cash flow. |
24,356 | 2020-10-29 00:00:00 UTC | ANALYSIS-U.S. drugmakers, bracing for price cuts, shift election support toward Democrats | ABBV | https://www.nasdaq.com/articles/analysis-u.s.-drugmakers-bracing-for-price-cuts-shift-election-support-toward-democrats | null | null | By Carl O'Donnell
NEW YORK, Oct 29 (Reuters) - The U.S. pharmaceutical industry, long a supporter of Republicans, is giving almost half its political donations to Democratic candidates in this year’s election, as companies look to fend off a threat to drug prices if Democrats gain power.
So far this year, industry-run ... | The biggest pharma PAC donations so far this year have come from Pfizer Inc PFE.N, Amgen Inc AMGN.O, Abbvie Inc ABBV.N and Johnson & Johnson JNJ.N, which all shifted support toward Democrats between 2016 and 2020, records show. The industry-level shift, based on support from non-profit political action committees affil... | The biggest pharma PAC donations so far this year have come from Pfizer Inc PFE.N, Amgen Inc AMGN.O, Abbvie Inc ABBV.N and Johnson & Johnson JNJ.N, which all shifted support toward Democrats between 2016 and 2020, records show. By Carl O'Donnell NEW YORK, Oct 29 (Reuters) - The U.S. pharmaceutical industry, long a supp... | The biggest pharma PAC donations so far this year have come from Pfizer Inc PFE.N, Amgen Inc AMGN.O, Abbvie Inc ABBV.N and Johnson & Johnson JNJ.N, which all shifted support toward Democrats between 2016 and 2020, records show. By Carl O'Donnell NEW YORK, Oct 29 (Reuters) - The U.S. pharmaceutical industry, long a supp... | The biggest pharma PAC donations so far this year have come from Pfizer Inc PFE.N, Amgen Inc AMGN.O, Abbvie Inc ABBV.N and Johnson & Johnson JNJ.N, which all shifted support toward Democrats between 2016 and 2020, records show. By Carl O'Donnell NEW YORK, Oct 29 (Reuters) - The U.S. pharmaceutical industry, long a supp... |
24,357 | 2020-10-29 00:00:00 UTC | AbbVie To Present New Analyses From Phase 3 Studies For RINVOQ - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie-to-present-new-analyses-from-phase-3-studies-for-rinvoq-quick-facts-2020-10-29 | null | null | (RTTNews) - AbbVie (ABBV) said it will present new analyses from pivotal phase 3 studies for RINVOQ (upadacitinib) in Atopic Dermatitis at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The company said these analyses show that significantly more atopic dermatitis patients treated wit... | (RTTNews) - AbbVie (ABBV) said it will present new analyses from pivotal phase 3 studies for RINVOQ (upadacitinib) in Atopic Dermatitis at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. Earlier in the current year, AbbVie reported top-line data from Measure Up 1 and Measure Up 2 showi... | (RTTNews) - AbbVie (ABBV) said it will present new analyses from pivotal phase 3 studies for RINVOQ (upadacitinib) in Atopic Dermatitis at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. Earlier in the current year, AbbVie reported top-line data from Measure Up 1 and Measure Up 2 showi... | Earlier in the current year, AbbVie reported top-line data from Measure Up 1 and Measure Up 2 showing upadacitinib (15 mg or 30 mg) met the co-primary endpoints of Eczema Area Severity Index 75 and a validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) score of 0/1 (clear or almost clear) at week ... | (RTTNews) - AbbVie (ABBV) said it will present new analyses from pivotal phase 3 studies for RINVOQ (upadacitinib) in Atopic Dermatitis at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. Earlier in the current year, AbbVie reported top-line data from Measure Up 1 and Measure Up 2 showi... |
24,358 | 2020-10-28 00:00:00 UTC | 7 Cutting-Edge Biotech Stocks for Tomorrow | ABBV | https://www.nasdaq.com/articles/7-cutting-edge-biotech-stocks-for-tomorrow-2020-10-28 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
When it comes to investing in biotech stocks, there are a number of reasons to be optimistic.
First, while politics can drive headlines, these businesses continue do well regardless of whether the White House is occupied by a Democrat or Republican. Second... | 7 Growth Stocks Running On Fumes Let’s look at seven cutting edge biotech stocks to consider owning for the future: Regeneron (NASDAQ:REGN) Bristol-Myers Squibb (NYSE:BMY) Amgen (NASDAQ:AMGN) Bluebird Bio (NASDAQ:BLUE) AbbVie (NYSE:ABBV) Vertex Pharmaceuticals (NASDAQ:VRTX) Mustang Bio (NASDAQ:MBIO) Regeneron (REGN) RE... | 7 Growth Stocks Running On Fumes Let’s look at seven cutting edge biotech stocks to consider owning for the future: Regeneron (NASDAQ:REGN) Bristol-Myers Squibb (NYSE:BMY) Amgen (NASDAQ:AMGN) Bluebird Bio (NASDAQ:BLUE) AbbVie (NYSE:ABBV) Vertex Pharmaceuticals (NASDAQ:VRTX) Mustang Bio (NASDAQ:MBIO) Regeneron (REGN) RE... | 7 Growth Stocks Running On Fumes Let’s look at seven cutting edge biotech stocks to consider owning for the future: Regeneron (NASDAQ:REGN) Bristol-Myers Squibb (NYSE:BMY) Amgen (NASDAQ:AMGN) Bluebird Bio (NASDAQ:BLUE) AbbVie (NYSE:ABBV) Vertex Pharmaceuticals (NASDAQ:VRTX) Mustang Bio (NASDAQ:MBIO) Regeneron (REGN) RE... | 7 Growth Stocks Running On Fumes Let’s look at seven cutting edge biotech stocks to consider owning for the future: Regeneron (NASDAQ:REGN) Bristol-Myers Squibb (NYSE:BMY) Amgen (NASDAQ:AMGN) Bluebird Bio (NASDAQ:BLUE) AbbVie (NYSE:ABBV) Vertex Pharmaceuticals (NASDAQ:VRTX) Mustang Bio (NASDAQ:MBIO) Regeneron (REGN) RE... |
24,359 | 2020-10-27 00:00:00 UTC | 3 Stocks You Can Still Buy on Sale in a Ridiculously Expensive Market | ABBV | https://www.nasdaq.com/articles/3-stocks-you-can-still-buy-on-sale-in-a-ridiculously-expensive-market-2020-10-27 | null | null | Make not mistake about it: The stock market is expensive right now. The S&P 500 Shiller cyclically adjusted price-to-earnings (CAPE) ratio, which measures price divided by the average of 10 years of earnings, is near its highest level over the last decade.
With valuations so high, you might think that finding good stoc... | The big pharma stock is priced so low mainly because investors are worried about AbbVie's growth prospects once top-selling autoimmune disease drug Humira begins to face biosimilar rivals in the U.S. in 2023. AbbVie AbbVie (NYSE: ABBV) shares currently trade at less than seven times expected earnings. Although that's a... | Like AbbVie and Bristol Myers Squibb, CVS Health also offers an attractive dividend that currently yields 3.3%. AbbVie AbbVie (NYSE: ABBV) shares currently trade at less than seven times expected earnings. The big pharma stock is priced so low mainly because investors are worried about AbbVie's growth prospects once to... | The big pharma stock is priced so low mainly because investors are worried about AbbVie's growth prospects once top-selling autoimmune disease drug Humira begins to face biosimilar rivals in the U.S. in 2023. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Keith Speights owns shares of AbbVie and Bristo... | Like AbbVie and Bristol Myers Squibb, CVS Health also offers an attractive dividend that currently yields 3.3%. AbbVie AbbVie (NYSE: ABBV) shares currently trade at less than seven times expected earnings. The big pharma stock is priced so low mainly because investors are worried about AbbVie's growth prospects once to... |
24,360 | 2020-10-21 00:00:00 UTC | FDA declines to approve Zosano's drug for relieving migraine headaches | ABBV | https://www.nasdaq.com/articles/fda-declines-to-approve-zosanos-drug-for-relieving-migraine-headaches-2020-10-21 | null | null | Adds details on FDA action, background
Oct 21 (Reuters) - The U.S. health regulator has declined to approve Zosano Pharma Corp's ZSAN.O experimental treatment to relieve pain after the onset of migraine headaches, citing issues with its delivery during clinical trials, the company said on Wednesday.
Shares of the compa... | An approval would have put Qtrypta in race with Biohaven's BHVN.N oral pill Nurtec ODT and AbbVie Inc's ABBV.N Ubrelvy, both of which belong to an emerging class of migraine treatments called calcitonin gene-related peptide (CGRP) inhibitors. Adds details on FDA action, background Oct 21 (Reuters) - The U.S. health reg... | An approval would have put Qtrypta in race with Biohaven's BHVN.N oral pill Nurtec ODT and AbbVie Inc's ABBV.N Ubrelvy, both of which belong to an emerging class of migraine treatments called calcitonin gene-related peptide (CGRP) inhibitors. The treatment Zosano is expected to compete with oral and injectable treatmen... | An approval would have put Qtrypta in race with Biohaven's BHVN.N oral pill Nurtec ODT and AbbVie Inc's ABBV.N Ubrelvy, both of which belong to an emerging class of migraine treatments called calcitonin gene-related peptide (CGRP) inhibitors. Adds details on FDA action, background Oct 21 (Reuters) - The U.S. health reg... | An approval would have put Qtrypta in race with Biohaven's BHVN.N oral pill Nurtec ODT and AbbVie Inc's ABBV.N Ubrelvy, both of which belong to an emerging class of migraine treatments called calcitonin gene-related peptide (CGRP) inhibitors. Adds details on FDA action, background Oct 21 (Reuters) - The U.S. health reg... |
24,361 | 2020-10-20 00:00:00 UTC | 7 Dividend Stocks To Buy For Big Returns In Your Bank Account | ABBV | https://www.nasdaq.com/articles/7-dividend-stocks-to-buy-for-big-returns-in-your-bank-account-2020-10-20 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Back in March, I produced an article recommending 10 stocks to buy for an income-generating portfolio. These were dividend stocks that didn’t just produce income; they also had an opportunity to deliver capital appreciation.
How have they done?
Not so well,... | Apollo Global Management (NYSE:APO) AbbVie (NYSE:ABBV) Bank of Nova Scotia (NYSE:BNS) Simon Property Group (NYSE:SPG) At the end of the day, it’s all about total return. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169">Source: Piotr Swat / Shutterstock.com Dividend Yield: 5.5% If not for t... | Apollo Global Management (NYSE:APO) AbbVie (NYSE:ABBV) Bank of Nova Scotia (NYSE:BNS) Simon Property Group (NYSE:SPG) At the end of the day, it’s all about total return. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169">Source: Piotr Swat / Shutterstock.com Dividend Yield: 5.5% If not for t... | Apollo Global Management (NYSE:APO) AbbVie (NYSE:ABBV) Bank of Nova Scotia (NYSE:BNS) Simon Property Group (NYSE:SPG) At the end of the day, it’s all about total return. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169">Source: Piotr Swat / Shutterstock.com Dividend Yield: 5.5% If not for t... | Apollo Global Management (NYSE:APO) AbbVie (NYSE:ABBV) Bank of Nova Scotia (NYSE:BNS) Simon Property Group (NYSE:SPG) At the end of the day, it’s all about total return. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169">Source: Piotr Swat / Shutterstock.com Dividend Yield: 5.5% If not for t... |
24,362 | 2020-10-20 00:00:00 UTC | ABBV Seeks Expanded Approval Of Rinvoq, APTX Cheered By PTSD Data, ENDP Snaps Up BSTC, LQDA On Watch | ABBV | https://www.nasdaq.com/articles/abbv-seeks-expanded-approval-of-rinvoq-aptx-cheered-by-ptsd-data-endp-snaps-up-bstc-lqda | null | null | (RTTNews) - Today's Daily Dose brings you news about AbbVie seeking expanded approval of RINVOQ in atopic dermatitis, Aptinyx's positive results in post-traumatic stress disorder trial, Endo International acquiring BioSpecifics Technologies, the merger agreement between Cleveland BioLabs and privately-held Cytocom, and... | (RTTNews) - Today's Daily Dose brings you news about AbbVie seeking expanded approval of RINVOQ in atopic dermatitis, Aptinyx's positive results in post-traumatic stress disorder trial, Endo International acquiring BioSpecifics Technologies, the merger agreement between Cleveland BioLabs and privately-held Cytocom, and... | (RTTNews) - Today's Daily Dose brings you news about AbbVie seeking expanded approval of RINVOQ in atopic dermatitis, Aptinyx's positive results in post-traumatic stress disorder trial, Endo International acquiring BioSpecifics Technologies, the merger agreement between Cleveland BioLabs and privately-held Cytocom, and... | (RTTNews) - Today's Daily Dose brings you news about AbbVie seeking expanded approval of RINVOQ in atopic dermatitis, Aptinyx's positive results in post-traumatic stress disorder trial, Endo International acquiring BioSpecifics Technologies, the merger agreement between Cleveland BioLabs and privately-held Cytocom, and... | (RTTNews) - Today's Daily Dose brings you news about AbbVie seeking expanded approval of RINVOQ in atopic dermatitis, Aptinyx's positive results in post-traumatic stress disorder trial, Endo International acquiring BioSpecifics Technologies, the merger agreement between Cleveland BioLabs and privately-held Cytocom, and... |
24,363 | 2020-10-19 00:00:00 UTC | AbbVie Submits Anti-Inflammatory Drug Rinvoq for FDA, Europe Approval for Atopic Dermatitis | ABBV | https://www.nasdaq.com/articles/abbvie-submits-anti-inflammatory-drug-rinvoq-for-fda-europe-approval-for-atopic-dermatitis | null | null | AbbVie (NYSE: ABBV) has taken an important step forward with one of its drug programs. The company announced Monday it has submitted its Rinvoq for approval to both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Rinvoq's submittal is for the treatment of moderate to severe atopic d... | As for the latest submittals, AbbVie quoted its vice chairman and president, Michael Severino, as saying that they "are an important step forward in our commitment to providing an additional treatment option for those who struggle with this debilitating and often underappreciated disease." AbbVie (NYSE: ABBV) has taken... | AbbVie (NYSE: ABBV) has taken an important step forward with one of its drug programs. AbbVie's submittals come on the heels of three successful phase 3 trials of the drug. The drug was discovered, and is being developed, exclusively by AbbVie. | 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. AbbVie (NYSE: ABBV) has taken an important step forward with one of its drug programs. AbbVie's submittals come on the heels of three successful phase 3 trials of the drug. | AbbVie (NYSE: ABBV) has taken an important step forward with one of its drug programs. AbbVie's submittals come on the heels of three successful phase 3 trials of the drug. The drug was discovered, and is being developed, exclusively by AbbVie. |
24,364 | 2020-10-19 00:00:00 UTC | Roche: FDA Approves Venclexta Combinations For Treatment Of Acute Myeloid Leukaemia | ABBV | https://www.nasdaq.com/articles/roche%3A-fda-approves-venclexta-combinations-for-treatment-of-acute-myeloid-leukaemia-2020 | null | null | (RTTNews) - Roche (RHHBY) announced the FDA has granted full approval of Venclexta (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukaemia in adults 75 years or older, or who have comorbidities that preclude use of intensive induct... | Venclexta is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, in the US, and commercialised by AbbVie, under the brand name Venclyxto outside of the US. (RTTNews) - Roche (RHHBY) announced the FDA has granted full approval of Venclexta (venetoclax) in combination with azacitidi... | Venclexta is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, in the US, and commercialised by AbbVie, under the brand name Venclyxto outside of the US. (RTTNews) - Roche (RHHBY) announced the FDA has granted full approval of Venclexta (venetoclax) in combination with azacitidi... | It is jointly commercialised by AbbVie and Genentech, in the US, and commercialised by AbbVie, under the brand name Venclyxto outside of the US. Venclexta is being developed by AbbVie and Roche. (RTTNews) - Roche (RHHBY) announced the FDA has granted full approval of Venclexta (venetoclax) in combination with azacitidi... | Venclexta is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, in the US, and commercialised by AbbVie, under the brand name Venclyxto outside of the US. (RTTNews) - Roche (RHHBY) announced the FDA has granted full approval of Venclexta (venetoclax) in combination with azacitidi... |
24,365 | 2020-10-18 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 10/18/2020 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-10-18-2020-2020-10-18 | null | null | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
AMERISOURCEBERGEN CORP. (ABC) is a lar... | Detailed Analysis of AMERISOURCEBERGEN CORP. Full Guru Analysis for ABC> Full Factor Report for ABC> ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Ana... | Detailed Analysis of AMERISOURCEBERGEN CORP. Full Guru Analysis for ABC> Full Factor Report for ABC> ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Ana... | Detailed Analysis of AMERISOURCEBERGEN CORP. Full Guru Analysis for ABC> Full Factor Report for ABC> ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Ana... | Detailed Analysis of AMERISOURCEBERGEN CORP. Full Guru Analysis for ABC> Full Factor Report for ABC> ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Ana... |
24,366 | 2020-10-17 00:00:00 UTC | Got $5,000? Here Are 2 Dividend Growth Stocks to Buy and Hold for Decades | ABBV | https://www.nasdaq.com/articles/got-%245000-here-are-2-dividend-growth-stocks-to-buy-and-hold-for-decades-2020-10-17 | null | null | If you are in a financial position to invest $5,000 in new stocks today, you will find no shortage of exciting options. If you would like to balance the potential for solid returns with long-term stability, dividend stocks might be the best place to start your search. Companies that have a history of regularly increasi... | Although the Illinois-based biopharmaceutical company may not be able to keep raising its dividend payments at such a high rate, there are plenty of reasons for investors to remain optimistic about AbbVie given the strong results it has been generating amid the COVID-19 pandemic. Two stocks that fit that profile are Ab... | Two stocks that fit that profile are AbbVie (NYSE: ABBV) and Visa (NYSE: V). AbbVie Drugmaker AbbVie is already an attractive income-generating investment; its current dividend yield of 5.5% is well above the S&P 500 average of around 2%. And AbbVie regularly boosts the size of those dividends payments. | Although the Illinois-based biopharmaceutical company may not be able to keep raising its dividend payments at such a high rate, there are plenty of reasons for investors to remain optimistic about AbbVie given the strong results it has been generating amid the COVID-19 pandemic. On July 31, AbbVie released its results... | Both of these dividend stocks are promising long-term investments even though each is underperforming the S&P 500 so far in 2020: ABBV data by YCharts In terms of dividend yield, AbbVie is the clear choice. Two stocks that fit that profile are AbbVie (NYSE: ABBV) and Visa (NYSE: V). AbbVie Drugmaker AbbVie is already a... |
24,367 | 2020-10-16 00:00:00 UTC | 5 High-Yield Stocks for 5%-Plus Dividend Payouts | ABBV | https://www.nasdaq.com/articles/5-high-yield-stocks-for-5-plus-dividend-payouts-2020-10-16 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It’s a difficult time to be an income investor. The S&P 500 index has rallied off of its 2020 lows and has returned to near-record highs, pushing the average dividend yield in the index below 2%. In addition, with interest rates near zero, fixed income yiel... | Philip Morris International (NYSE:PM) Enbridge Inc. (NYSE:ENB) Unum Group (NYSE:UNM) AbbVie Inc. (NYSE:ABBV) International Business Machines (NYSE:IBM) High-Yield Stocks: Philip Morris International (PM) Source: defotoberg / Shutterstock.com Philip Morris International is one of the world’s largest tobacco companies, w... | Philip Morris International (NYSE:PM) Enbridge Inc. (NYSE:ENB) Unum Group (NYSE:UNM) AbbVie Inc. (NYSE:ABBV) International Business Machines (NYSE:IBM) High-Yield Stocks: Philip Morris International (PM) Source: defotoberg / Shutterstock.com Philip Morris International is one of the world’s largest tobacco companies, w... | Philip Morris International (NYSE:PM) Enbridge Inc. (NYSE:ENB) Unum Group (NYSE:UNM) AbbVie Inc. (NYSE:ABBV) International Business Machines (NYSE:IBM) High-Yield Stocks: Philip Morris International (PM) Source: defotoberg / Shutterstock.com Philip Morris International is one of the world’s largest tobacco companies, w... | Philip Morris International (NYSE:PM) Enbridge Inc. (NYSE:ENB) Unum Group (NYSE:UNM) AbbVie Inc. (NYSE:ABBV) International Business Machines (NYSE:IBM) High-Yield Stocks: Philip Morris International (PM) Source: defotoberg / Shutterstock.com Philip Morris International is one of the world’s largest tobacco companies, w... |
24,368 | 2020-10-15 00:00:00 UTC | Validea Joel Greenblatt Strategy Daily Upgrade Report - 10/15/2020 | ABBV | https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-10-15-2020-2020-10-15 | null | null | The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.
JOHN B. SANFILIPPO & SON, INC. (JBSS) is a small-cap growth stock in the Food Processing industry. The ... | Detailed Analysis of JOHN B. SANFILIPPO & SON, INC. Full Guru Analysis for JBSS Full Factor Report for JBSS ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full G... | Detailed Analysis of JOHN B. SANFILIPPO & SON, INC. Full Guru Analysis for JBSS Full Factor Report for JBSS ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV More details on Validea's Joel Greenbla... | Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV More details on Validea's Joel Greenblatt strategy Joel Greenblatt Stock Ideas About Joel Greenblatt: In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way ... | Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV More details on Validea's Joel Greenblatt strategy Joel Greenblatt Stock Ideas About Joel Greenblatt: In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way ... |
24,369 | 2020-10-15 00:00:00 UTC | 7 Value Stocks To Buy in an Overvalued Market | ABBV | https://www.nasdaq.com/articles/7-value-stocks-to-buy-in-an-overvalued-market-2020-10-15 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If there’s one collective benefit associated with the novel coronavirus, it’s that an increasing number of people have given their financial future a rethink. Before the pandemic, many financial advisors noted that the current generation of young Americans ... | Verso (NYSE:VRS) AbbVie (NYSE:ABBV) Merck (NYSE:MRK) AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169">Source: Piotr Swat / Shutterstock.com As I’ve mentioned before, 2020 could go down as the year of the pivot. Included in the collective search for a solution was AbbVie, which extended its... | Verso (NYSE:VRS) AbbVie (NYSE:ABBV) Merck (NYSE:MRK) AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169">Source: Piotr Swat / Shutterstock.com As I’ve mentioned before, 2020 could go down as the year of the pivot. Included in the collective search for a solution was AbbVie, which extended its... | 7 Consumer Stocks for an Impenetrable Defense While AbbVie isn’t exactly making headlines this year, it’s poised to become one of the more viable value stocks in the post-pandemic era. Verso (NYSE:VRS) AbbVie (NYSE:ABBV) Merck (NYSE:MRK) AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169">Sou... | Still, no one is rushing to buy ABBV stock for its coronavirus narrative. Verso (NYSE:VRS) AbbVie (NYSE:ABBV) Merck (NYSE:MRK) AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169">Source: Piotr Swat / Shutterstock.com As I’ve mentioned before, 2020 could go down as the year of the pivot. |
24,370 | 2020-10-14 00:00:00 UTC | Better Buy: AbbVie vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-johnson-johnson-2020-10-14 | null | null | Many large pharmaceutical companies fall into the category of widow-and-orphan stocks -- stocks that have a relatively high dividend yield and pose very low risks to investors. An investment in a widow-and-orphan stock is intended to grow over time, provide income, and generally go untouched for long periods. When eval... | Shortly after the split, AbbVie launched Humira, a treatment for rheumatoid arthritis, psoriasis, and Crohn's disease, which made up more than half the company's revenue in 2019. AbbVie completed its acquisition of Allergan for $63 billion in May in an attempt to diversify its revenue streams and reduce the risk inhere... | JNJ EPS LT Growth Estimates data by YCharts The final tally Despite a similar growth rate and a poorer cash flow yield, the market thinks a dollar of Johnson & Johnson earnings is more than twice as valuable as the same dollar generated by AbbVie. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are two pharmaceut... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are two pharmaceutical companies that fit the widow-and-orphan description. So similar, yet so different Pharmaceutical companies like AbbVie and Johnson & Johnson all develop, manufacture, and market drugs, but are wildly different businesses when you dig into the ... | AbbVie's free cash flow yield is 10.5% compared to 4.3% for Johnson & Johnson. The chart below shows that estimates of Johnson & Johnson and AbbVie's growth over the next three to five years are very similar. In five years, AbbVie may look more like Johnson & Johnson than it does today. |
24,371 | 2020-10-13 00:00:00 UTC | NIH starts clinical trial testing antibody treatments in COVID-19 patients | ABBV | https://www.nasdaq.com/articles/nih-starts-clinical-trial-testing-antibody-treatments-in-covid-19-patients-2020-10-13 | null | null | Oct 13 (Reuters) - The U.S. National Institutes of Health (NIH) said on Tuesday it has started a study to evaluate two antibody treatments in COVID-19 patients as part of the agency's program to identify promising drugs to help tackle the new coronavirus.
The trial will test AbbVie Inc's ABBV.K psoriasis drug risankizu... | The trial will test AbbVie Inc's ABBV.K psoriasis drug risankizumab along with Gilead Sciences' GILD.O antiviral remdesivir, compared to a placebo and remdesivir. Oct 13 (Reuters) - The U.S. National Institutes of Health (NIH) said on Tuesday it has started a study to evaluate two antibody treatments in COVID-19 patien... | The trial will test AbbVie Inc's ABBV.K psoriasis drug risankizumab along with Gilead Sciences' GILD.O antiviral remdesivir, compared to a placebo and remdesivir. Oct 13 (Reuters) - The U.S. National Institutes of Health (NIH) said on Tuesday it has started a study to evaluate two antibody treatments in COVID-19 patien... | The trial will test AbbVie Inc's ABBV.K psoriasis drug risankizumab along with Gilead Sciences' GILD.O antiviral remdesivir, compared to a placebo and remdesivir. Oct 13 (Reuters) - The U.S. National Institutes of Health (NIH) said on Tuesday it has started a study to evaluate two antibody treatments in COVID-19 patien... | The trial will test AbbVie Inc's ABBV.K psoriasis drug risankizumab along with Gilead Sciences' GILD.O antiviral remdesivir, compared to a placebo and remdesivir. Oct 13 (Reuters) - The U.S. National Institutes of Health (NIH) said on Tuesday it has started a study to evaluate two antibody treatments in COVID-19 patien... |
24,372 | 2020-10-13 00:00:00 UTC | AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for October 14, 2020 | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-ex-dividend-date-scheduled-for-october-14-2020-2020-10-13 | null | null | AbbVie Inc. (ABBV) will begin trading ex-dividend on October 14, 2020. A cash dividend payment of $1.18 per share is scheduled to be paid on November 16, 2020. Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that ABBV has paid the same... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABBV's forecasted earnings growth in 2020 as 16.83%, compared to an industry average of 7.6%. For more information on the declaration, record and payment dates, visit the ABBV Divi... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. ABBV's current earnings per share, an indicator of a company's profitability, is $4.7. The following ETF(s) have ABBV as a top-10 holding: WisdomTree U.S. High Dividend Fund (DHS) Invesco Dynamic Pharmaceuticals ET... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABBV Dividend History page. The following ETF(s) have ABBV as a top-10 holding: WisdomTree U.S. High Dividend Fund (DHS) Invesco Dynamic ... | The following ETF(s) have ABBV as a top-10 holding: WisdomTree U.S. High Dividend Fund (DHS) Invesco Dynamic Pharmaceuticals ETF (PJP) VanEck Vectors ETF Trust (DURA) First Trust Morningstar ETF (FDL) First Trust Nasdaq Pharmaceuticals ETF (FTXH). AbbVie Inc. (ABBV) will begin trading ex-dividend on October 14, 2020. S... |
24,373 | 2020-10-11 00:00:00 UTC | Is Gilead Sciences a Buy? | ABBV | https://www.nasdaq.com/articles/is-gilead-sciences-a-buy-2020-10-11 | null | null | I recently came across a quote from Woodrow Wilson highlighting the difference between things that follow a set of rules and those that react to changes and evolve. Wilson called the latter "accountable to Darwin," the former to Newton. It occurred to me that many investors, myself included, often fall into the trap of... | The chart also shows the drop-off over the past few years as Gilead's hepatitis C drug faced competition from AbbVie (NYSE: ABBV) and cannibalization from the company's own generic replacement. A real-life example is Gilead Sciences (NASDAQ: GILD), where management is attempting to repeat a strategy that led to a soari... | The chart also shows the drop-off over the past few years as Gilead's hepatitis C drug faced competition from AbbVie (NYSE: ABBV) and cannibalization from the company's own generic replacement. If investing followed a logical set of rules, a successful strategy in the past would naturally be successful the next time. W... | The chart also shows the drop-off over the past few years as Gilead's hepatitis C drug faced competition from AbbVie (NYSE: ABBV) and cannibalization from the company's own generic replacement. GILD Total Long Term Debt (Annual) data by YCharts Daniel O'Day took the helm in early 2019 and promptly spent $5.1 billion fo... | The chart also shows the drop-off over the past few years as Gilead's hepatitis C drug faced competition from AbbVie (NYSE: ABBV) and cannibalization from the company's own generic replacement. GILD Revenue (Annual) data by YCharts In anticipation of the drop in sales, management has made several large acquisitions ove... |
24,374 | 2020-10-05 00:00:00 UTC | HIV treatment has no benefit for hospitalised COVID-19 patients - study | ABBV | https://www.nasdaq.com/articles/hiv-treatment-has-no-benefit-for-hospitalised-covid-19-patients-study-2020-10-05 | null | null | LONDON, Oct 5 (Reuters) - A combination of antiviral drugs usually used to treat HIV has no beneficial effect in patients hospitalised with COVID-19, a peer-reviewed study said on Monday, confirming the initial results of a large-scale randomised trial of the drug.
British scientists running the RECOVERY trial at the U... | AbbVie Inc's ABBV.N Kaletra is a combination of the drugs lopinavir and ritonavir, used together to fight HIV. British scientists running the RECOVERY trial at the University of Oxford in June said interim results had convincingly ruled out any meaningful benefit of lopinavir-ritonavir in lowering mortality among hospi... | AbbVie Inc's ABBV.N Kaletra is a combination of the drugs lopinavir and ritonavir, used together to fight HIV. LONDON, Oct 5 (Reuters) - A combination of antiviral drugs usually used to treat HIV has no beneficial effect in patients hospitalised with COVID-19, a peer-reviewed study said on Monday, confirming the initia... | AbbVie Inc's ABBV.N Kaletra is a combination of the drugs lopinavir and ritonavir, used together to fight HIV. LONDON, Oct 5 (Reuters) - A combination of antiviral drugs usually used to treat HIV has no beneficial effect in patients hospitalised with COVID-19, a peer-reviewed study said on Monday, confirming the initia... | AbbVie Inc's ABBV.N Kaletra is a combination of the drugs lopinavir and ritonavir, used together to fight HIV. LONDON, Oct 5 (Reuters) - A combination of antiviral drugs usually used to treat HIV has no beneficial effect in patients hospitalised with COVID-19, a peer-reviewed study said on Monday, confirming the initia... |
24,375 | 2020-10-04 00:00:00 UTC | These 3 Value Stocks are Absurdly Cheap Right Now | ABBV | https://www.nasdaq.com/articles/these-3-value-stocks-are-absurdly-cheap-right-now-2020-10-04 | null | null | As most stock market observers know, the indexes have recently reached record highs. Nonetheless, individual stocks often experience their own bull and bear swings independent of the indexes -- so even during times like these, investors can still find value stocks.
Many of the stocks currently on sale probably should t... | Stocks such as AbbVie (NYSE: ABBV), Prudential Financial (NYSE: PRU), and Qualcomm (NASDAQ: QCOM) offer such potential. AbbVie Once the pharma division of Abbott Laboratories, AbbVie has bolstered its fortunes primarily with revenues from the sale of the world's best-selling drug, Humira, since becoming an independent ... | Additionally, with a low valuation, impressive profit growth, and a generous dividend, AbbVie should show profits for investors for years to come. Stocks such as AbbVie (NYSE: ABBV), Prudential Financial (NYSE: PRU), and Qualcomm (NASDAQ: QCOM) offer such potential. AbbVie Once the pharma division of Abbott Laboratorie... | Additionally, with a low valuation, impressive profit growth, and a generous dividend, AbbVie should show profits for investors for years to come. Stocks such as AbbVie (NYSE: ABBV), Prudential Financial (NYSE: PRU), and Qualcomm (NASDAQ: QCOM) offer such potential. AbbVie Once the pharma division of Abbott Laboratorie... | Stocks such as AbbVie (NYSE: ABBV), Prudential Financial (NYSE: PRU), and Qualcomm (NASDAQ: QCOM) offer such potential. AbbVie Once the pharma division of Abbott Laboratories, AbbVie has bolstered its fortunes primarily with revenues from the sale of the world's best-selling drug, Humira, since becoming an independent ... |
24,376 | 2020-10-01 00:00:00 UTC | After Hours Most Active for Oct 1, 2020 : VICI, AAPL, SLB, ABBV, SGMS, MSFT, HST, MNST, APA, RUN, GE, VZ | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-for-oct-1-2020-%3A-vici-aapl-slb-abbv-sgms-msft-hst-mnst-apa-run-ge | null | null | The NASDAQ 100 After Hours Indicator is down -.97 to 11,582.23. The total After hours volume is currently 71,431,546 shares traded.
The following are the most active stocks for the after hours session:
VICI Properties Inc. (VICI) is unchanged at $23.72, with 6,720,551 shares traded. VICI's current last sale is 94.88%... | AbbVie Inc. (ABBV) is +0.06 at $87.20, with 2,951,534 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2021. | As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". AbbVie Inc. (ABBV) is +0.06 at $87.20, with 2,951,534 shares traded. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range". | AbbVie Inc. (ABBV) is +0.06 at $87.20, with 2,951,534 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The total After hours volume is currently 71,431,546 shares traded. | As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". AbbVie Inc. (ABBV) is +0.06 at $87.20, with 2,951,534 shares traded. As reported by Zacks, the current mean recommendation for SLB is in the "buy range". |
24,377 | 2020-10-01 00:00:00 UTC | Best ETFs for 2020: The AdvisorShares Vice ETF Saved by SAM and TMO | ABBV | https://www.nasdaq.com/articles/best-etfs-for-2020%3A-the-advisorshares-vice-etf-saved-by-sam-and-tmo-2020-10-01 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
This article is a part of InvestorPlace.com’s Best ETFs for 2020 contest. The InvestorPlace Staff’s pick for the contest is the AdvisorShares Vice ETF (NASDAQ:ACT).
Summer was not very kind to the AdvisorShares Vice ETF (NASDAQ:ACT). Since it was last writt... | Citing his confidence about the company’s upcoming launch of Truly Iced Tea Hard Seltzer, due out in January, Guggenheim analyst Laurent Grandet holds a “buy” rating on the stock, taking his price target up to $1,142 from $977. Take comfort in the fact that ACT also has significant exposure to the alcohol, gambling and... | The InvestorPlace Staff’s pick for the contest is the AdvisorShares Vice ETF (NASDAQ:ACT). In its most recent portfolio manager review, Dan Ahrens commented that May through July 2020, the Fund “returned 14.07 % on its net asset value (NAV) and 13.77% on its market price, while the S&P 500 returned 12.87%.” ACT’s Top H... | The InvestorPlace Staff’s pick for the contest is the AdvisorShares Vice ETF (NASDAQ:ACT). In its most recent portfolio manager review, Dan Ahrens commented that May through July 2020, the Fund “returned 14.07 % on its net asset value (NAV) and 13.77% on its market price, while the S&P 500 returned 12.87%.” ACT’s Top H... | The InvestorPlace Staff’s pick for the contest is the AdvisorShares Vice ETF (NASDAQ:ACT). The ACT ETF portfolio’s weight in TMO went up to 8.27% from 7.79% in July. Not Just Cannabis Cautious investors might be weary of getting involved with an ETF that has 40% of its portfolio in cannabis-related revenue, especially ... |
24,378 | 2020-10-01 00:00:00 UTC | 7 Dividend Stocks Perfect for a Retiree’s Portfolio | ABBV | https://www.nasdaq.com/articles/7-dividend-stocks-perfect-for-a-retirees-portfolio-2020-10-01 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
When the U.S. Federal Reserve cut the rate to zero, investors that depended on safe, fixed income instruments suffered. The sharply lower bond yields and lack of return from cash forced retirees to invest in the stock market. And because most sectors rose s... | The companies are: 7 Marijuana Stocks to Buy That Will Survive 2020 AbbVie Inc. (NYSE:ABBV) Altria Group (NYSE:MO) AbbVie Inc. (ABBV) ABBV) website and logo on mobile phone" width="300" height="169">Source: Piotr Swat / Shutterstock.com First up on this list of dividend stocks to buy is AbbVie. Drug manufacturer AbbVie... | Assuming a modest discount rate of 7% and revenue growing in the single digit, dividend stocks to buy like AbbVie stock is worth at least $100: Metrics Range Conclusion Discount Rate 7.5% – 6.5% 7% Perpetuity Growth Rate 3.5% – 4.5% 4% Fair Value $65.04 – $171.72 $100.61 Model courtesy of finbox. The companies are: 7 M... | Assuming a modest discount rate of 7% and revenue growing in the single digit, dividend stocks to buy like AbbVie stock is worth at least $100: Metrics Range Conclusion Discount Rate 7.5% – 6.5% 7% Perpetuity Growth Rate 3.5% – 4.5% 4% Fair Value $65.04 – $171.72 $100.61 Model courtesy of finbox. The companies are: 7 M... | The companies are: 7 Marijuana Stocks to Buy That Will Survive 2020 AbbVie Inc. (NYSE:ABBV) Altria Group (NYSE:MO) AbbVie Inc. (ABBV) ABBV) website and logo on mobile phone" width="300" height="169">Source: Piotr Swat / Shutterstock.com First up on this list of dividend stocks to buy is AbbVie. Drug manufacturer AbbVie... |
24,379 | 2020-10-01 00:00:00 UTC | AbbVie: New Brunswick, British Columbia List SKYRIZI On Its Provincial Formulary | ABBV | https://www.nasdaq.com/articles/abbvie%3A-new-brunswick-british-columbia-list-skyrizi-on-its-provincial-formulary-2020-10-01 | null | null | (RTTNews) - AbbVie (ABBV) said SKYRIZI (risankizumab) is now listed as a special authorization drug or exception drug status on the formularies of New Brunswick, Yukon, British Columbia, and Newfoundland and Labrador for the treatment of moderate to severe plaque psoriasis.
SKYRIZI is a humanized immunoglobulin monoclo... | (RTTNews) - AbbVie (ABBV) said SKYRIZI (risankizumab) is now listed as a special authorization drug or exception drug status on the formularies of New Brunswick, Yukon, British Columbia, and Newfoundland and Labrador for the treatment of moderate to severe plaque psoriasis. SKYRIZI is part of a collaboration between Bo... | (RTTNews) - AbbVie (ABBV) said SKYRIZI (risankizumab) is now listed as a special authorization drug or exception drug status on the formularies of New Brunswick, Yukon, British Columbia, and Newfoundland and Labrador for the treatment of moderate to severe plaque psoriasis. SKYRIZI is part of a collaboration between Bo... | (RTTNews) - AbbVie (ABBV) said SKYRIZI (risankizumab) is now listed as a special authorization drug or exception drug status on the formularies of New Brunswick, Yukon, British Columbia, and Newfoundland and Labrador for the treatment of moderate to severe plaque psoriasis. SKYRIZI is part of a collaboration between Bo... | (RTTNews) - AbbVie (ABBV) said SKYRIZI (risankizumab) is now listed as a special authorization drug or exception drug status on the formularies of New Brunswick, Yukon, British Columbia, and Newfoundland and Labrador for the treatment of moderate to severe plaque psoriasis. SKYRIZI is part of a collaboration between Bo... |
24,380 | 2020-09-30 00:00:00 UTC | US court voids $448 million award against AbbVie, AndroGel partner | ABBV | https://www.nasdaq.com/articles/us-court-voids-%24448-million-award-against-abbvie-androgel-partner-2020-09-30 | null | null | Sept 30 (Reuters) - A federal appeals court on Wednesday reversed an order that had required AbbVie Inc ABBV.N and a partner to disgorge $448 million in profit, in antitrust litigation brought by the U.S. Federal Trade Commission related to the testosterone replacement drug AndroGel.
The 3rd U.S. Circuit Court of Appea... | Sept 30 (Reuters) - A federal appeals court on Wednesday reversed an order that had required AbbVie Inc ABBV.N and a partner to disgorge $448 million in profit, in antitrust litigation brought by the U.S. Federal Trade Commission related to the testosterone replacement drug AndroGel. It also upheld an order finding Abb... | Sept 30 (Reuters) - A federal appeals court on Wednesday reversed an order that had required AbbVie Inc ABBV.N and a partner to disgorge $448 million in profit, in antitrust litigation brought by the U.S. Federal Trade Commission related to the testosterone replacement drug AndroGel. It also upheld an order finding Abb... | Sept 30 (Reuters) - A federal appeals court on Wednesday reversed an order that had required AbbVie Inc ABBV.N and a partner to disgorge $448 million in profit, in antitrust litigation brought by the U.S. Federal Trade Commission related to the testosterone replacement drug AndroGel. It also upheld an order finding Abb... | Sept 30 (Reuters) - A federal appeals court on Wednesday reversed an order that had required AbbVie Inc ABBV.N and a partner to disgorge $448 million in profit, in antitrust litigation brought by the U.S. Federal Trade Commission related to the testosterone replacement drug AndroGel. It also upheld an order finding Abb... |
24,381 | 2020-09-30 00:00:00 UTC | AbbVie withdraws uterine fibroids drug from Canada | ABBV | https://www.nasdaq.com/articles/abbvie-withdraws-uterine-fibroids-drug-from-canada-2020-09-30 | null | null | Sept 30 (Reuters) - AbbVie Inc ABBV.N said on Wednesday it was voluntarily withdrawing its drug to treat noncancerous growths in the uterus from the Canadian market, following reports of severe liver injury.
The decision follows reports on rare cases of severe liver injury needing liver transplantation in Europe, the c... | Sept 30 (Reuters) - AbbVie Inc ABBV.N said on Wednesday it was voluntarily withdrawing its drug to treat noncancerous growths in the uterus from the Canadian market, following reports of severe liver injury. Patients and doctors have been advised to halt the intake of the drug and seek alternate medication, AbbVie said... | Sept 30 (Reuters) - AbbVie Inc ABBV.N said on Wednesday it was voluntarily withdrawing its drug to treat noncancerous growths in the uterus from the Canadian market, following reports of severe liver injury. Patients and doctors have been advised to halt the intake of the drug and seek alternate medication, AbbVie said... | Sept 30 (Reuters) - AbbVie Inc ABBV.N said on Wednesday it was voluntarily withdrawing its drug to treat noncancerous growths in the uterus from the Canadian market, following reports of severe liver injury. Patients and doctors have been advised to halt the intake of the drug and seek alternate medication, AbbVie said... | Sept 30 (Reuters) - AbbVie Inc ABBV.N said on Wednesday it was voluntarily withdrawing its drug to treat noncancerous growths in the uterus from the Canadian market, following reports of severe liver injury. Patients and doctors have been advised to halt the intake of the drug and seek alternate medication, AbbVie said... |
24,382 | 2020-09-30 00:00:00 UTC | Oxford to study anti-inflammatory drug Humira as potential COVID-19 treatment | ABBV | https://www.nasdaq.com/articles/oxford-to-study-anti-inflammatory-drug-humira-as-potential-covid-19-treatment-2020-09-30 | null | null | Adding details throughout
LONDON, Sept 30 (Reuters) - Oxford University said on Wednesday it would study whether the world's best-selling prescription medicine, adalimumab, was an effective treatment for COVID-19 patients, the latest effort to repurpose existing drugs as potential coronavirus therapies.
Adalimumab, sol... | Adalimumab, sold by AbbVie ABBV.N under the brand name Humira, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Adding details throughout LONDON, Sept 30 (Reuters) - Oxford University said on Wednesday it would study whether the world's best-selling prescription medicine, adalimum... | Adalimumab, sold by AbbVie ABBV.N under the brand name Humira, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Adding details throughout LONDON, Sept 30 (Reuters) - Oxford University said on Wednesday it would study whether the world's best-selling prescription medicine, adalimum... | Adalimumab, sold by AbbVie ABBV.N under the brand name Humira, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Adding details throughout LONDON, Sept 30 (Reuters) - Oxford University said on Wednesday it would study whether the world's best-selling prescription medicine, adalimum... | Adalimumab, sold by AbbVie ABBV.N under the brand name Humira, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. The trial, called AVID-CC, will be aimed at treating people in the community, especially in care homes, the university said. But there are not yet effective therapies fo... |
24,383 | 2020-09-30 00:00:00 UTC | Better Buy: CRISPR Therapeutics vs. Editas Medicine | ABBV | https://www.nasdaq.com/articles/better-buy%3A-crispr-therapeutics-vs.-editas-medicine-2020-09-30 | null | null | You can't use traditional means to compare CRISPR Therapeutics (NASDAQ: CRSP) and Editas Medicine (NASDAQ: EDIT) because they are emerging biotech companies with little revenue, and several years between their current efforts and any form of profitability.
Both of these companies are developing medicines that edit gene... | Its collaboration is with Allergan (NYSE: AGN), which was bought by pharma magnate AbbVie (NYSE: ABBV) in May. Jim Halley owns shares of AbbVie. The first is CTX001, which CRISPR has been developing with Vertex Pharmaceuticals (NASDAQ: VRTX) as a treatment for two genetic blood disorders: severe sickle cell disease (SC... | Its collaboration is with Allergan (NYSE: AGN), which was bought by pharma magnate AbbVie (NYSE: ABBV) in May. Jim Halley owns shares of AbbVie. You can't use traditional means to compare CRISPR Therapeutics (NASDAQ: CRSP) and Editas Medicine (NASDAQ: EDIT) because they are emerging biotech companies with little revenu... | Its collaboration is with Allergan (NYSE: AGN), which was bought by pharma magnate AbbVie (NYSE: ABBV) in May. Jim Halley owns shares of AbbVie. You can't use traditional means to compare CRISPR Therapeutics (NASDAQ: CRSP) and Editas Medicine (NASDAQ: EDIT) because they are emerging biotech companies with little revenu... | Its collaboration is with Allergan (NYSE: AGN), which was bought by pharma magnate AbbVie (NYSE: ABBV) in May. Jim Halley owns shares of AbbVie. The first is CTX001, which CRISPR has been developing with Vertex Pharmaceuticals (NASDAQ: VRTX) as a treatment for two genetic blood disorders: severe sickle cell disease (SC... |
24,384 | 2020-09-28 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Bank of America, Eiger BioPharmaceuticals, Pangaea Logistics | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-boeing-bank-of-america-eiger-biopharmaceuticals-pangaea | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stocks jumped on Monday, bouncing back from the longest weekly losing streak in a year for the S&P 500 and the Dow, with technology, banks and travel s... | The top three S&P 500 .PG.INX percentage gainers: ** Devon Energy Corp , up 12.4% ** Apache Corp , up 7.5% ** Boeing Co , up 6.7% The top three S&P 500 .PL.INX percentage losers: ** DexCom Inc , down 2.6% ** Westrock Co , down 2.5% ** Regeneron Pharmaceuticals Inc , down 2% The top three NYSE .PG.N percentage gainers: ... | The top three S&P 500 .PG.INX percentage gainers: ** Devon Energy Corp , up 12.4% ** Apache Corp , up 7.5% ** Boeing Co , up 6.7% The top three S&P 500 .PL.INX percentage losers: ** DexCom Inc , down 2.6% ** Westrock Co , down 2.5% ** Regeneron Pharmaceuticals Inc , down 2% The top three NYSE .PG.N percentage gainers: ... | The top three S&P 500 .PG.INX percentage gainers: ** Devon Energy Corp , up 12.4% ** Apache Corp , up 7.5% ** Boeing Co , up 6.7% The top three S&P 500 .PL.INX percentage losers: ** DexCom Inc , down 2.6% ** Westrock Co , down 2.5% ** Regeneron Pharmaceuticals Inc , down 2% The top three NYSE .PG.N percentage gainers: ... | The top three S&P 500 .PG.INX percentage gainers: ** Devon Energy Corp , up 12.4% ** Apache Corp , up 7.5% ** Boeing Co , up 6.7% The top three S&P 500 .PL.INX percentage losers: ** DexCom Inc , down 2.6% ** Westrock Co , down 2.5% ** Regeneron Pharmaceuticals Inc , down 2% The top three NYSE .PG.N percentage gainers: ... |
24,385 | 2020-09-28 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Chesapeake Utilities, OpGen, Nikola, Perceptron | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-chesapeake-utilities-opgen-nikola-perceptron-2020-09-28 | null | null | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street surged at the open on Monday following the longest weekly losing streak in a year for the S&P 500 and the Dow, with investors piling into shares... | The top three S&P 500 .PG.INX percentage gainers: ** Lincoln National Corp , up 5.5% ** Boeing Co , up 5.4% ** National Oilwell Varco Inc , up 5.2% The top three S&P 500 .PL.INX percentage losers: ** Westrock Co , down 3.3% ** DexCom Inc , down 1.3% ** Regeneron Pharmaceuticals Inc , down 1.3% The top three NYSE .PG.N ... | The top three S&P 500 .PG.INX percentage gainers: ** Lincoln National Corp , up 5.5% ** Boeing Co , up 5.4% ** National Oilwell Varco Inc , up 5.2% The top three S&P 500 .PL.INX percentage losers: ** Westrock Co , down 3.3% ** DexCom Inc , down 1.3% ** Regeneron Pharmaceuticals Inc , down 1.3% The top three NYSE .PG.N ... | The top three S&P 500 .PG.INX percentage gainers: ** Lincoln National Corp , up 5.5% ** Boeing Co , up 5.4% ** National Oilwell Varco Inc , up 5.2% The top three S&P 500 .PL.INX percentage losers: ** Westrock Co , down 3.3% ** DexCom Inc , down 1.3% ** Regeneron Pharmaceuticals Inc , down 1.3% The top three NYSE .PG.N ... | The top three S&P 500 .PG.INX percentage gainers: ** Lincoln National Corp , up 5.5% ** Boeing Co , up 5.4% ** National Oilwell Varco Inc , up 5.2% The top three S&P 500 .PL.INX percentage losers: ** Westrock Co , down 3.3% ** DexCom Inc , down 1.3% ** Regeneron Pharmaceuticals Inc , down 1.3% The top three NYSE .PG.N ... |
24,386 | 2020-09-28 00:00:00 UTC | AbbVie: FDA Grants Orphan Drug & Fast Track Designations For Elezanumab | ABBV | https://www.nasdaq.com/articles/abbvie%3A-fda-grants-orphan-drug-fast-track-designations-for-elezanumab-2020-09-28 | null | null | (RTTNews) - AbbVie (ABBV) announced the U.S. FDA has granted Orphan Drug and Fast Track designations for elezanumab, an investigational treatment for patients following spinal cord injury. Elezanumab is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries, multiple sclerosis and acute i... | (RTTNews) - AbbVie (ABBV) announced the U.S. FDA has granted Orphan Drug and Fast Track designations for elezanumab, an investigational treatment for patients following spinal cord injury. Currently AbbVie is partnering with the Shirley Ryan AbilityLab, and MC10 in a pilot study involving 20 spinal cord injury patients... | (RTTNews) - AbbVie (ABBV) announced the U.S. FDA has granted Orphan Drug and Fast Track designations for elezanumab, an investigational treatment for patients following spinal cord injury. Currently AbbVie is partnering with the Shirley Ryan AbilityLab, and MC10 in a pilot study involving 20 spinal cord injury patients... | (RTTNews) - AbbVie (ABBV) announced the U.S. FDA has granted Orphan Drug and Fast Track designations for elezanumab, an investigational treatment for patients following spinal cord injury. Currently AbbVie is partnering with the Shirley Ryan AbilityLab, and MC10 in a pilot study involving 20 spinal cord injury patients... | (RTTNews) - AbbVie (ABBV) announced the U.S. FDA has granted Orphan Drug and Fast Track designations for elezanumab, an investigational treatment for patients following spinal cord injury. Currently AbbVie is partnering with the Shirley Ryan AbilityLab, and MC10 in a pilot study involving 20 spinal cord injury patients... |
24,387 | 2020-09-28 00:00:00 UTC | 3 Top Dividend Stocks With Yields Over 5% | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-with-yields-over-5-2020-09-28 | null | null | It's been a rough year for dividend stocks, with companies slashing payouts right and left in an effort to hold on to waning cash reserves. While this has naturally caused considerable stress for investors, it's also made it easier to discern the winners that have stayed the course in the market downturn.Â
If this yea... | AbbVie Biopharmaceutical giant AbbVie's (NYSE: ABBV) dividend yields 5.5%. AbbVie is also a Dividend Aristocrat that has raised its payout for 47 consecutive years in a row (counting its time as part of Abbott Labs), putting it within reach of being crowned a Dividend King.  AbbVie has reported stellar financial resu... |  AbbVie has reported stellar financial results during the pandemic, most recently with its Q2 earnings report released July 31. The company's neuroscience portfolio, which is largely comprised of products obtained in the Allergan acquisition, experienced a 100% increase in net revenue growth. Looking at AbbVie's tota... | AbbVie's revenue in the second quarter shot up by more than 26% year over year to $10.4 billion, while revenues in the company's hematologic oncology and immunology portfolios grew by 25.5% and 8.1% compared with the same period last year. The company's neuroscience portfolio, which is largely comprised of products obt... | AbbVie Biopharmaceutical giant AbbVie's (NYSE: ABBV) dividend yields 5.5%. AbbVie is also a Dividend Aristocrat that has raised its payout for 47 consecutive years in a row (counting its time as part of Abbott Labs), putting it within reach of being crowned a Dividend King.  AbbVie has reported stellar financial resu... |
24,388 | 2020-09-24 00:00:00 UTC | 3 Stocks to Buy Ahead of the Next Market Crash | ABBV | https://www.nasdaq.com/articles/3-stocks-to-buy-ahead-of-the-next-market-crash-2020-09-24 | null | null | If you want to survive the next stock market crash, you have to think big -- as in huge pharmaceutical companies such as Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Eli Lilly (NYSE: LLY). These healthcare companies have the staying power and attractive dividends to keep rolling.
AbbVie stock is about flat y... | That purchase will help AbbVie expand its pipeline to survive increasing biosimilar competition for anti-inflammation therapy Humira, which is the world's top-selling drug. The expected decline of Humira sales presents some risk, but AbbVie has the most attractive dividend -- one that appears safe, with a trailing-12-m... | If you want to survive the next stock market crash, you have to think big -- as in huge pharmaceutical companies such as Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Eli Lilly (NYSE: LLY). AbbVie: Encouraging dividends and growth AbbVie is a Dividend Aristocrat with 46 consecutive years of dividend growth, c... | If you want to survive the next stock market crash, you have to think big -- as in huge pharmaceutical companies such as Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Eli Lilly (NYSE: LLY). AbbVie stock is about flat year to date, and while it had a brief dip when the recession first hit, the recovery of its ... | AbbVie: Encouraging dividends and growth AbbVie is a Dividend Aristocrat with 46 consecutive years of dividend growth, counting its time as part of Abbott Labs. If you want to survive the next stock market crash, you have to think big -- as in huge pharmaceutical companies such as Johnson & Johnson (NYSE: JNJ), AbbVie ... |
24,389 | 2020-09-22 00:00:00 UTC | Does This Pharma Company's Lead Asset Make it a Buy Today? | ABBV | https://www.nasdaq.com/articles/does-this-pharma-companys-lead-asset-make-it-a-buy-today-2020-09-22 | null | null | Bipolar disorder is relatively common, with 2.8% of adults, or 6 million Americans, reporting symptoms over a 12-month period. But the market is underserved; in particular, only a limited number of pharmaceutical companies have succeeded in launching treatments for bipolar-related depression. Hence, the recent clinical... | AstraZeneca's (NYSE: AZN) Seroquel, Sumitomo Dainippon Pharma's Latuda, and AbbVie's (NYSE: ABBV) Vraylar -- are all earning close to $1 billion in annual revenue within a few years of launch. Hence, the recent clinical success of Intra-Cellular Therapies' (NASDAQ: ITCI) antipsychotic drug, lumateperone, in the treatme... | AstraZeneca's (NYSE: AZN) Seroquel, Sumitomo Dainippon Pharma's Latuda, and AbbVie's (NYSE: ABBV) Vraylar -- are all earning close to $1 billion in annual revenue within a few years of launch. Hence, the recent clinical success of Intra-Cellular Therapies' (NASDAQ: ITCI) antipsychotic drug, lumateperone, in the treatme... | AstraZeneca's (NYSE: AZN) Seroquel, Sumitomo Dainippon Pharma's Latuda, and AbbVie's (NYSE: ABBV) Vraylar -- are all earning close to $1 billion in annual revenue within a few years of launch. A closer look at bipolar depression trials for oral lumateperone Intra-Cellular Therapies has reported strong results for lumat... | AstraZeneca's (NYSE: AZN) Seroquel, Sumitomo Dainippon Pharma's Latuda, and AbbVie's (NYSE: ABBV) Vraylar -- are all earning close to $1 billion in annual revenue within a few years of launch. Besides bipolar-related depression, the company plans to launch a phase 3 trial for oral lumateperone in treating major depress... |
24,390 | 2020-09-18 00:00:00 UTC | 2 Great Pharma Stocks to Buy in the Next Market Crash | ABBV | https://www.nasdaq.com/articles/2-great-pharma-stocks-to-buy-in-the-next-market-crash-2020-09-18 | null | null | AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are stable giants in the pharmaceutical industry. Both companies have an extensive array of products on the market, not to mention plenty of promising drugs in development. Between their attractive dividend yields in excess of 4% and their steady long-term growth p... | How could AbbVie possibly be worth a buy when it doesn't have enough cash to cover its short-term expenses, never mind its mountain of looming debt payments? AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are stable giants in the pharmaceutical industry. AbbVie, while profitable, has taken on a tremendous $87.5... | SPY data by YCharts AbbVie seeks to shed its debts After buying cosmetics company Allergan this year for $63 billion in cash and stock, AbbVie was left with tens of billions of dollars in long-term debt. AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are stable giants in the pharmaceutical industry. AbbVie, whi... | SPY data by YCharts AbbVie seeks to shed its debts After buying cosmetics company Allergan this year for $63 billion in cash and stock, AbbVie was left with tens of billions of dollars in long-term debt. AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are stable giants in the pharmaceutical industry. AbbVie, whi... | AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are stable giants in the pharmaceutical industry. AbbVie, while profitable, has taken on a tremendous $87.5 billion in debt, and it may not have enough cash on hand to cover its short-term debt obligations. SPY data by YCharts AbbVie seeks to shed its debts After b... |
24,391 | 2020-09-18 00:00:00 UTC | 3 Cheap Stocks You Can Buy and Hold for Decades | ABBV | https://www.nasdaq.com/articles/3-cheap-stocks-you-can-buy-and-hold-for-decades-2020-09-18 | null | null | Even with the recent pullback, the stock market remains near all-time highs. There aren't many stocks with attractive valuations. Of those, quite a few aren't the kinds of stocks you'd want to touch with a 10-foot pole.
That doesn't mean that there aren't some appealing stocks available at bargain prices, though. Here ... | AbbVie doesn't have to generate a lot of growth to still provide a solid total return to investors because its dividend yields around 5.2%. With its share price at current levels, CVS Health -- like AbbVie and Bristol Myers Squibb -- appears to be a cheap stock to buy now and hold for the long term. AbbVie AbbVie (NYSE... | AbbVie AbbVie (NYSE: ABBV) shares trade at only 7.4 times expected earnings. The big pharma stock is available at a discount primarily because investors aren't sure how AbbVie will perform once its top-selling drug Humira begins to face biosimilar rivals in the U.S. beginning in 2023. But there are plenty of reasons to... | The big pharma stock is available at a discount primarily because investors aren't sure how AbbVie will perform once its top-selling drug Humira begins to face biosimilar rivals in the U.S. beginning in 2023. With its share price at current levels, CVS Health -- like AbbVie and Bristol Myers Squibb -- appears to be a c... | With its share price at current levels, CVS Health -- like AbbVie and Bristol Myers Squibb -- appears to be a cheap stock to buy now and hold for the long term. AbbVie AbbVie (NYSE: ABBV) shares trade at only 7.4 times expected earnings. The big pharma stock is available at a discount primarily because investors aren't... |
24,392 | 2020-09-17 00:00:00 UTC | 6 Dividend Stocks To Buy For Stable Yield And Growth Potential | ABBV | https://www.nasdaq.com/articles/6-dividend-stocks-to-buy-for-stable-yield-and-growth-potential-2020-09-17 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Investors love dividend stocks for a few reasons. First and foremost, that sweet dividend income.
After all, investors like when an investment returns money in the form of dividends, and has the potential to appreciate in price. That growth potential is usu... | 20 Election Stocks to Buy if Joe Biden Wins in 2020 Here are 6 dividend stocks to buy for yield and growth: AbbVie (NYSE:ABBV) Carlisle Company (NYSE:CSL) Skyworks Solutions (NASDAQ:SWKS) Coca-Cola (NYSE:KO) Automatic Data Processing (NASDAQ:ADP) Johnson & Johnson (NYSE:JNJ) Excessive dividend payout ratios stifle the ... | 20 Election Stocks to Buy if Joe Biden Wins in 2020 Here are 6 dividend stocks to buy for yield and growth: AbbVie (NYSE:ABBV) Carlisle Company (NYSE:CSL) Skyworks Solutions (NASDAQ:SWKS) Coca-Cola (NYSE:KO) Automatic Data Processing (NASDAQ:ADP) Johnson & Johnson (NYSE:JNJ) Excessive dividend payout ratios stifle the ... | 20 Election Stocks to Buy if Joe Biden Wins in 2020 Here are 6 dividend stocks to buy for yield and growth: AbbVie (NYSE:ABBV) Carlisle Company (NYSE:CSL) Skyworks Solutions (NASDAQ:SWKS) Coca-Cola (NYSE:KO) Automatic Data Processing (NASDAQ:ADP) Johnson & Johnson (NYSE:JNJ) Excessive dividend payout ratios stifle the ... | 20 Election Stocks to Buy if Joe Biden Wins in 2020 Here are 6 dividend stocks to buy for yield and growth: AbbVie (NYSE:ABBV) Carlisle Company (NYSE:CSL) Skyworks Solutions (NASDAQ:SWKS) Coca-Cola (NYSE:KO) Automatic Data Processing (NASDAQ:ADP) Johnson & Johnson (NYSE:JNJ) Excessive dividend payout ratios stifle the ... |
24,393 | 2020-09-17 00:00:00 UTC | New York charges Johnson & Johnson with insurance fraud over opioid claims | ABBV | https://www.nasdaq.com/articles/new-york-charges-johnson-johnson-with-insurance-fraud-over-opioid-claims-2020-09-17-0 | null | null | Adds comment from New York governor, additional allegations
NEW YORK, Sept 17 (Reuters) - New York state filed civil charges on Thursday accusing Johnson & Johnson JNJ.N of insurance fraud for downplaying the risks of opioid painkillers, including to doctors and elderly patients.
Governor Andrew Cuomo said the charges ... | Johnson & Johnson and its Janssen Pharmaceuticals affiliate were accused of specifically targeting elderly patients for opioid treatment despite the risks, and in marketing materials characterizing opioid addiction as a myth. New York said Johnson & Johnson manufactured opioid products in the state such as the fentanyl... | Adds comment from New York governor, additional allegations NEW YORK, Sept 17 (Reuters) - New York state filed civil charges on Thursday accusing Johnson & Johnson JNJ.N of insurance fraud for downplaying the risks of opioid painkillers, including to doctors and elderly patients. Governor Andrew Cuomo said the charges ... | Adds comment from New York governor, additional allegations NEW YORK, Sept 17 (Reuters) - New York state filed civil charges on Thursday accusing Johnson & Johnson JNJ.N of insurance fraud for downplaying the risks of opioid painkillers, including to doctors and elderly patients. Governor Andrew Cuomo said the charges ... | Adds comment from New York governor, additional allegations NEW YORK, Sept 17 (Reuters) - New York state filed civil charges on Thursday accusing Johnson & Johnson JNJ.N of insurance fraud for downplaying the risks of opioid painkillers, including to doctors and elderly patients. Governor Andrew Cuomo said the charges ... |
24,394 | 2020-09-17 00:00:00 UTC | New York charges Johnson & Johnson with insurance fraud over opioid claims | ABBV | https://www.nasdaq.com/articles/new-york-charges-johnson-johnson-with-insurance-fraud-over-opioid-claims-2020-09-17 | null | null | NEW YORK, Sept 17 (Reuters) - New York state filed civil charges on Thursday accusing Johnson & Johnson JNJ.N of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients.
Governor Andrew Cuomo said the charges by New York's Department of Financial Services in that regulator's opioi... | NEW YORK, Sept 17 (Reuters) - New York state filed civil charges on Thursday accusing Johnson & Johnson JNJ.N of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients. Governor Andrew Cuomo said the charges by New York's Department of Financial Services in that regulator's opioi... | NEW YORK, Sept 17 (Reuters) - New York state filed civil charges on Thursday accusing Johnson & Johnson JNJ.N of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients. Governor Andrew Cuomo said the charges by New York's Department of Financial Services in that regulator's opioi... | NEW YORK, Sept 17 (Reuters) - New York state filed civil charges on Thursday accusing Johnson & Johnson JNJ.N of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients. Governor Andrew Cuomo said the charges by New York's Department of Financial Services in that regulator's opioi... | NEW YORK, Sept 17 (Reuters) - New York state filed civil charges on Thursday accusing Johnson & Johnson JNJ.N of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients. Governor Andrew Cuomo said the charges by New York's Department of Financial Services in that regulator's opioi... |
24,395 | 2020-09-16 00:00:00 UTC | AbbVie To Present At The Morgan Stanley Healthcare Conference; Webcast At 11:00 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-to-present-at-the-morgan-stanley-healthcare-conference-webcast-at-11%3A00-am-et-2020 | null | null | (RTTNews) - AbbVie (ABBV) will participate in the Morgan Stanley 18th Annual Global Healthcare Conference.
The event is scheduled to begin at 11:00 AM ET on September 16, 2020
To access the live webcast, log on to http://investors.abbvie.com
The views and opinions expressed herein are the views and opinions of the auth... | (RTTNews) - AbbVie (ABBV) will participate in the Morgan Stanley 18th Annual Global Healthcare Conference. The event is scheduled to begin at 11:00 AM ET on September 16, 2020 To access the live webcast, log on to http://investors.abbvie.com The views and opinions expressed herein are the views and opinions of the auth... | (RTTNews) - AbbVie (ABBV) will participate in the Morgan Stanley 18th Annual Global Healthcare Conference. The event is scheduled to begin at 11:00 AM ET on September 16, 2020 To access the live webcast, log on to http://investors.abbvie.com The views and opinions expressed herein are the views and opinions of the auth... | (RTTNews) - AbbVie (ABBV) will participate in the Morgan Stanley 18th Annual Global Healthcare Conference. The event is scheduled to begin at 11:00 AM ET on September 16, 2020 To access the live webcast, log on to http://investors.abbvie.com The views and opinions expressed herein are the views and opinions of the auth... | (RTTNews) - AbbVie (ABBV) will participate in the Morgan Stanley 18th Annual Global Healthcare Conference. The event is scheduled to begin at 11:00 AM ET on September 16, 2020 To access the live webcast, log on to http://investors.abbvie.com The views and opinions expressed herein are the views and opinions of the auth... |
24,396 | 2020-09-15 00:00:00 UTC | Great Yield and Packed Pipeline Signal a Buy for AbbVie | ABBV | https://www.nasdaq.com/articles/great-yield-and-packed-pipeline-signal-a-buy-for-abbvie-2020-09-15 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It’s surprising to me that among dividend-focused investors, AbbVie (NYSE:ABBV) isn’t a hot topic of discussion. Perhaps that’s because AbbVie stock tends to get pigeonholed as a Big Pharma bet. Meanwhile, dividend investors sometimes tend to focus their at... | A major moneymaker for AbbVie, Humira is designed to treat Crohn’s disease, ulcerative colitis, psoriasis, multiple forms of arthritis and other conditions. That being duly noted, AbbVie is a respected pharma giant and with sweet dividend payouts to tide you over, awaiting the outcome of clinical trials won’t likely be... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s surprising to me that among dividend-focused investors, AbbVie (NYSE:ABBV) isn’t a hot topic of discussion. As for the price action, AbbVie stock has retraced somewhat from its 52-week high of $101.28. Perhaps that’s because AbbVie stock tends to get p... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s surprising to me that among dividend-focused investors, AbbVie (NYSE:ABBV) isn’t a hot topic of discussion. A Closer Look at AbbVie Stock I’ve been teasing AbbVie’s dividend yield, so now it’s time for the big reveal. 20 Election Stocks to Buy if Donal... | Heck, even deep value investors can find something to like about AbbVie stock. InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s surprising to me that among dividend-focused investors, AbbVie (NYSE:ABBV) isn’t a hot topic of discussion. Perhaps that’s because AbbVie stock tends to get pigeonholed as a... |
24,397 | 2020-09-13 00:00:00 UTC | 2 Biotech Stocks with Jaw-Dropping Growth Potential | ABBV | https://www.nasdaq.com/articles/2-biotech-stocks-with-jaw-dropping-growth-potential-2020-09-13 | null | null | Biotech stocks have proven time and again to be outstanding growth vehicles for risk-tolerant investors. Underscoring this point, companies like Axsome Therapeutics, Immunomedics, and Novavax have each generated enormous returns on capital for investors within an exceedingly short period of time.
Which biotech stocks ... | The biotech's stock has taken flight in 2020 for three key reasons: AbbVie and Gilead Sciences have both recently invested huge sums of money in CD47-based cancer therapies -- a novel immune checkpoint pathway. What that means is unclear exactly, but AbbVie has been fairly successful at picking winners when it comes to... | The biotech's stock has taken flight in 2020 for three key reasons: AbbVie and Gilead Sciences have both recently invested huge sums of money in CD47-based cancer therapies -- a novel immune checkpoint pathway. It is also interesting to note that AbbVie passed over Trillium in its quest for a CD47 asset. What that mean... | The biotech's stock has taken flight in 2020 for three key reasons: AbbVie and Gilead Sciences have both recently invested huge sums of money in CD47-based cancer therapies -- a novel immune checkpoint pathway. It is also interesting to note that AbbVie passed over Trillium in its quest for a CD47 asset. What that mean... | The biotech's stock has taken flight in 2020 for three key reasons: AbbVie and Gilead Sciences have both recently invested huge sums of money in CD47-based cancer therapies -- a novel immune checkpoint pathway. It is also interesting to note that AbbVie passed over Trillium in its quest for a CD47 asset. What that mean... |
24,398 | 2020-09-11 00:00:00 UTC | Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% | ABBV | https://www.nasdaq.com/articles/dividend-aristocrat-abbvie-declares-its-latest-payout-yield-is-5.3-2020-09-12 | null | null | One of the top dividend stocks in the healthcare sector is getting ready to hand out some cash to shareholders yet again. AbbVie (NYSE: ABBV) announced Friday that its board of directors has declared a fresh quarterly dividend of $1.18 per share.
This is to be distributed on Nov. 16 to investors of record as of Oct. 15... | AbbVie (NYSE: ABBV) announced Friday that its board of directors has declared a fresh quarterly dividend of $1.18 per share. On Friday, AbbVie shares traded essentially sideways, more or less in step with the development of the wider stock market. AbbVie has been a steady dividend payer and lifter since it was spun off... | AbbVie (NYSE: ABBV) announced Friday that its board of directors has declared a fresh quarterly dividend of $1.18 per share. AbbVie has been a steady dividend payer and lifter since it was spun off from Abbott Laboratories (NYSE: ABT) in 2013. Since Abbott is a Dividend Aristocrat (an S&P 500 index component that has i... | 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. AbbVie (NYSE: ABBV) announced Friday that its board of directors has declared a fresh quarterly dividend of $1.18 per share. AbbVie has been a steady dividend payer and lifter since it was spun off... | AbbVie (NYSE: ABBV) announced Friday that its board of directors has declared a fresh quarterly dividend of $1.18 per share. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie has been a steady dividend payer and lifter since i... |
24,399 | 2020-09-11 00:00:00 UTC | 2 Top Dividend Stocks to Buy in a Stock Market Crash | ABBV | https://www.nasdaq.com/articles/2-top-dividend-stocks-to-buy-in-a-stock-market-crash-2020-09-11 | null | null | Over the past six months, the stock market and overall economy have seemed to be on completely different pages. Despite a high unemployment rate and grim economic outlook, stocks have rallied since March 23, with the S&P 500 gaining more than 40% over this period. The rise doesn't mean that volatility is a thing of the... | In that spirit, here are two top dividend stocks in the pharma sector you can buy on the dip and hold with confidence when another downturn comes: AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN). With a strong lineup, solid pipeline, stellar dividend history, juicy yield, and a conservative payout ratio, dividend-seeking ... | With a strong lineup, solid pipeline, stellar dividend history, juicy yield, and a conservative payout ratio, dividend-seeking investors would do well to buy shares of AbbVie, especially if they become cheaper because of a market crash. And while Amgen isn't as attractively priced as AbbVie -- it currently has a forwar... | In that spirit, here are two top dividend stocks in the pharma sector you can buy on the dip and hold with confidence when another downturn comes: AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN). ABBV data by YCharts 1. AbbVie Income-seeking investors want assurance that a company won't suspend its payouts -- even during ... | AbbVie's current dividend yield is 5.11%, compared to an average of 1.71% for the S&P 500, and the company boasts a conservative cash payout ratio of 47.5%. In that spirit, here are two top dividend stocks in the pharma sector you can buy on the dip and hold with confidence when another downturn comes: AbbVie (NYSE: AB... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.